

Nanoparticle-Based Drug Delivery Systems for Inflammatory Bowel Disease Treatment

Jian Gao¹, Jiannan Li², Zengyou Luo¹, Hongyong Wang³, Zhiming Ma¹

¹Department of Gastrointestinal Nutrition and Hernia Surgery, The Second Hospital of Jilin University, Changchun, People's Republic of China; ²Department of Colorectal and Anal Surgery, The Second Hospital of Jilin University, Changchun, People's Republic of China; ³Department of Radiotherapy, The Second Hospital of Jilin University, Changchun, People's Republic of China

Correspondence: Zhiming Ma, Department of Gastrointestinal Nutrition and Hernia Surgery, The Second Hospital of Jilin University, Changchun, People's Republic of China, Email mazhiming@jlu.edu.cn

Abstract: Inflammatory bowel disease (IBD) is a chronic, non-specific inflammatory condition characterized by recurring inflammation of the intestinal mucosa. However, the existing IBD treatments are ineffective and have serious side effects. The etiology of IBD is multifactorial and encompasses immune, genetic, environmental, dietary, and microbial factors. The nanoparticles (NPs) developed based on specific targeting methodologies exhibit great potential as nanotechnology advances. Nanoparticles are defined as particles between 1 and 100 nm in size. Depending on their size and surface functionality, NPs exhibit different properties. A variety of nanoparticle types have been employed as drug carriers for the treatment of inflammatory bowel disease (IBD), with encouraging outcomes observed in experimental models. They increase the bioavailability of drugs and enable targeted drug delivery, promoting localized treatment and thus enhancing efficacy. Nevertheless, numerous challenges persist in the translation from nanomedicine to clinical application, including enhanced formulations and preparation techniques, enhanced drug safety profiles, and so forth. In the future, it will be necessary for scientists and clinicians to collaborate in order to study disease mechanisms, develop new drug delivery strategies, and screen new nanomedicines. Nevertheless, numerous challenges persist in the translation from nanomedicine to clinical application, including enhanced formulations and preparation techniques, enhanced drug safety profiles, and so forth. In the future, it will be necessary for scientists and clinicians to collaborate in order to study disease mechanisms, develop new drug delivery strategies, and screen new nanomedicines.

Keywords: nanoparticles, inflammatory bowel diseases, targeted delivery, passive targeting, active targeting, drug delivery system

Introduction

Inflammatory bowel disease (IBD) is a chronic, non-specific inflammatory disease that affects the intestinal tract.¹ The prevalence of IBD is highest in North America and Europe, where it is estimated that 6.9 million people globally have it.^{2,3} The prevalence of inflammatory bowel disease (IBD) has been on the rise in newly industrialised countries over the past two decades, reaching a point of accelerated growth.^{2,3} In contrast, the Western world is currently experiencing a phase of stabilisation in terms of incidence, with prevalence expected to remain at approximately one percent by 2030.⁴ This presents a significant challenge to global public health.

The two main types of IBD are Crohn's disease,¹ which typically affects the gastrointestinal tract in a segmented structure, and ulcerative colitis, where lesions primarily affect the colonic mucosa and submucosa in a continuous pattern.⁵ Abdominal pain, diarrhea, bloody stools, and weight loss are only a few of the primary clinical symptoms. Additionally, the most typical extra-intestinal problems primarily affect the joints, skin, eyes, and bile ducts, significantly impacting the quality of life.^{6,7}

Although the exact cause of IBD is still unknown,⁸ several factors, including immunological, gastrointestinal, environmental, nutritional, and microbial infections, may be linked to IBD.^{9,10} The pathophysiology of IBD is characterised by a loss of function of the mucosal epithelial cell system, local immune cell responses, dysbiosis of the gut microbiota, and changes in the local environment of the tissues. Despite the lack of curative treatment for the eradication of IBD,¹¹ these physiological and pathological changes provide new targets for the development of targeted drug delivery

systems for IBD. Inducing an initial remission and preventing relapse during remission are the general principles of pharmacological treatment of IBD.¹² Aminosalicylates, antibiotics, glucocorticoids, immunomodulators, and biologics are commonly used in conventional drug therapy for IBD. These drugs aim to improve the mucosal lining of the colon and repair, induce and maintain inflammatory remission.

A significant obstacle to effective treatment is drug delivery to the diseased site. Parenteral, transoral, and rectal enema are traditional delivery methods for IBD.¹³ Because of its low cost of production, convenience of handling, and good compliance, the oral dose form is regarded as the most desirable and acceptable form of daily administration for treating IBD.^{14,15} However, the active ingredient is absorbed by the mucosal membrane of the alimentary tract and distributed throughout the body following oral formulation. The development of systemic adverse drug reactions can impact treatment outcomes, as they are influenced by notable variations in the gastrointestinal environment and between healthy and inflamed intestinal regions. Intrarectal administration can potentially deliver tissue concentrations even higher than oral administration and provide local treatment for IBD in the distal colon.¹⁶ However, conventional enemas are ineffective in patient compliance because of their short retention time in the colorectal lumen and the need for frequent administration.^{17,18} Therefore, it is imperative to design effective drug delivery systems (DDSs) to deliver more drugs to the site of inflammation precisely.

Medical nanomaterials have come a long way in the last few years. Its goal is to design and manufacture materials with novel properties and functions on the scale of 1 to 1000 nm, namely nanoparticles (NPs).¹⁹ NPs are small, have a large surface area, and have a unique shape. As a novel bioactive carrier, NPs increase the local drug concentration at the disease site to maximize drug efficacy. They have been significant in gastrointestinal diseases.²⁰ Significant advancements have been made in nanoparticle-based strategies for the treatment of inflammation and tumours. Several chronic diseases, such as osteoarthritis,²¹ rheumatoid arthritis²² and skin conditions,²³ have been treated with NSAIDs (non-steroidal anti-inflammatory drugs) or Glucocorticoids as either a primary or adjunctive treatment option. These diseases often require prolonged anti-inflammatory therapy. The developments in nanotechnology have markedly enhanced the accumulation of anti-inflammatory agents. Targeting is the key to treating IBD. Targeted delivery of IBD reduces systemic drug exposure and related side effects by releasing the drug directly into the inflamed tissue, lowering the frequency of administration to obtain the required dosage, and minimizing the non-specific distribution of the drug throughout the body. Currently, various NPs, including polymeric NPs, lipid-based NPs, liposomes, silica NPs, nanogels, shell-core NPs, and particle NPs, are used as drug carriers for treating IBD.²⁴

Several targeting strategies have been investigated so far, and they are often predicted by different physiological factors between the colonic and proximal sections of the gastrointestinal tract.²⁵ Its three primary divisions are passive, active, and hybrid targeting. This paper has reviewed and discussed the targeting and functional roles of nanopharmaceutical agents in treating IBD (Tables 1–3). We have summarised the effectiveness and limitations of different types of delivery systems for the treatment of IBD (Table 4). Additionally, we have summarized the challenges and possible avenues for further study in this area.

Passive Targeting

The primary determinants of passive targeting are the physicochemical characteristics of the particle carrier itself (size, charge, etc.) and the local microenvironment.¹⁰¹ Thus, passive targeting methods for IBD may be achieved by altering the nanosize of the NPs and exploring the local microenvironmental characteristics of the intestine (pH, reactive oxygen species [ROS] levels, and overexpression of the digestive enzymes).

Targeting Based on Enhanced Permeability and Retention (EPR) Effect

In normal tissues, microvascular gaps seem to be densified and structurally intact. In contrast, to enable particle adherence, the inflammatory intestine produces more mucus than normal tissue, and the small size of NPs increases their capacity to penetrate the mucus.¹⁰² Furthermore, increased endothelial barrier permeability has been linked to epithelial injury and loss of intercellular tight junction chains produced by various factors (inflammatory mediators, cytokines, etc.).^{103,104} NPs are taken up and retained in the inflammatory site by the infiltrating immune and inflammatory cells, such as macrophages, dendritic cells, and neutrophils.¹⁰⁵ This is known as the epithelial increased permeability and retention effect (EPR) (Figure 1A).¹⁰⁶ As a result, NPs can prolong their stay at the inflammation site by passively targeting it.

Table I The Passive Targeting and Functional Effects of Nanoformulations for IBD Treatment

| IBD | Type of Targeting | Targeting Mechanism | Delivery route | Loaded Agents/Cargo | NPs Delivery System | Model | Main Results | Ref |
|-----|-------------------|----------------------|----------------------|---------------------|--------------------------------|---|--|------|
| UC | Passive | EPR effect | Oral delivery | Bud | NLCs | DSS mice model, J774 cells line model | High encapsulation rate; lower level of inflammatory factors; longer drug residence duration in the colon. | [26] |
| UC | Passive | EPR effect | Oral delivery | Cyclosporin A | Protamine nanocapsules | Jurkat cells line model | High encapsulation efficiency and good drug loading capacity decrease IL-2 secretion. | [27] |
| UC | Passive | EPR effect | Oral delivery | Celecoxib | Nanomixed micelles | Acetic acid rabbit model | The nanomixed micelles have good anti-inflammatory and antioxidant properties that help alleviate colitis. | [28] |
| UC | Passive | EPR effect | Oral delivery | Bud | PLGA | Oxazolone mice model | The NPs target the colonic inflammatory site to release drugs. | [29] |
| UC | Passive | EPR effect | Oral delivery | 5-ASA | Hemoglobin NPs | Caco-2 and HT-29 cell line models | High rate of drug release combined with excellent biocompatibility and biodegradability. | [30] |
| UC | Passive | EPR effect | Oral delivery | Rifaximin | Tamarind gum NPs | TNBS rats model | The NPs exhibit positive therapeutic effects on colitis and function as antioxidants. | [31] |
| UC | Passive | EPR effect | Intravenous delivery | H2S donors | ST-H2S liposomes | DSS mice model, Caco-2 model, and RAW 264.7 cell line model | ST-H2S liposomes have an excellent immunomodulatory potential. | [32] |
| UC | Passive | EPR effect | Oral delivery | Oleuropein | NLCs | DSS mice model, J774 cells line model | Anti-inflammatory and antioxidant effects via lowering TNF- α and ROS production and secretion. | [33] |
| UC | Passive | EPR effect | Oral delivery | IFX | EAC-IFX-L and AC-IFX-L | DSS mice model | AC-IFX-L and EAC-IFX-L showed better symptom relief than the DSS treatment group. | [34] |
| UC | Passive | Lysozyme-triggered | Oral delivery | Vancomycin | Chitosan-polyaniline microgels | Caco-2 cell line model | Specific inflammatory colonization, inhibition of <i>Staphylococcus aureus</i> , superior biosafety. | [35] |
| UC | Passive | Azoreductase enzymes | Oral delivery | Hydrocortisone | MSs | DSS mice model | Excellent stability, drug release rate, and capacity to regulate intestinal flora. | [36] |
| UC | Passive | Esterases | Oral delivery | 5-ASA | SiNP | TNBS mice model | High adhesion and low toxicity. | [37] |
| UC | Passive | Esterases | Oral delivery | Dex | PPNP | DSS mice model | Biosafety, specific targeting ability, and antioxidant activity. | [38] |

(Continued)

Table I (Continued).

| IBD | Type of Targeting | Targeting Mechanism | Delivery route | Loaded Agents/Cargo | NPs Delivery System | Model | Main Results | Ref |
|-----|-------------------|------------------------------|--|------------------------------|--|---|--|------|
| UC | Passive | Acid sphingomyelinase | Vein injection | Fluorescent agent ICG | Sphingomyelin liposomes | DSS mice model and Caco-2 cell line model | Target-specific liposomes facilitate macrophage uptake. | [39] |
| UC | Passive | Azoreductase enzymes | – | Ornidazole and sulfasalazine | Sulfasalazine-polyethylene glycol micelles | HEK 293 cell line model | The excellent stability nanomicelles release the loaded drug by being activated by azo reductase. | [40] |
| UC | Passive | Azoreductase triggered | Oral delivery | M-Saf M-Bud | MSMs | Mice model | Capable of delivering drugs to targeted colonic sites | [41] |
| UC | Passive | α -amylase responsive | Oral delivery | Dex | HES-CUR NPs | DSS mice model | The excellent anti-inflammatory and antioxidant properties of NPs enable multi-drug combination therapy. | [42] |
| UC | Passive | ROS-responsive | Oral delivery | Bud and Tpl | Bud-ATK-Tpl | DSS mice model and RAW264.7 cell line model | High drug release to minimize adverse effects; colitis treatment that combines anti-inflammatory and antioxidant treatment. | [43] |
| UC | Passive | ROS-responsive | Oral delivery | Tpl | OxbCD | DSS mice and TNBS mice model | Excellent biosafety and antioxidant function are achieved via drug molecule release from multiple components that eliminate ROS. | [44] |
| UC | Passive | ROS responsive | Oral delivery | Silymarin | SiRNP | DSS mice model and RAW 264.7 cells model | Effective elimination of ROS, biodegradable, and improved bioavailability of the drug. | [45] |
| UC | Passive | ROS-responsive | Oral delivery | SeM | SeM@EM | DSS mice model and HT29 cell line model | SeM@EM improves drug adherence, alleviates inflammation, and promotes the growth of beneficial intestinal microbiota. | [46] |
| UC | Passive | ROS-responsive | Intravenous and subcutaneous injection | – | OxbCD NPs | Guinea pigs model B16F10 cells and MDA-MB-231 cells lines model | Superior ROS sensitivity and biocompatibility. | [47] |
| UC | Passive | pH-sensitive | Oral delivery | OVA | PLGA NPs | DSS mice model and Caco-2 cell line model | Superior stability and specificity in targeting the colon. | [14] |
| UC | Passive | pH-sensitive | Oral delivery | Bud | Eudragit S 100/ Capryol 90 nanocapsules | Acetic acid rat model | Favorable drug release rate and effective targeting for colonic drug delivery. | [48] |
| UC | Passive | pH-sensitive | Oral delivery | BBR | PLGA NPs | DSS mice model | Dual drug release properties to reduce the frequency of drug administration. | [49] |

(Continued)

Table I (Continued).

| IBD | Type of Targeting | Targeting Mechanism | Delivery route | Loaded Agents/Cargo | NPs Delivery System | Model | Main Results | Ref |
|-----|-------------------|---------------------|----------------|----------------------|---|---|---|------|
| UC | Passive | pH-sensitive | Oral delivery | Cur | Polyacrylamide-grafted-xanthan gum NPs | Acetic acid rat model | NPs have a high degree of colonic targeting and alleviate myeloperoxidase and nitrite levels to relieve colitis symptoms. | [50] |
| UC | Passive | pH-sensitive | Oral delivery | IL-1Ra | Alginate/chitosan microcapsules | DSS mice model | Microcapsules can release the drug in situ in the colon, reducing systemic adverse effects. | [51] |
| UC | Passive | pH-sensitive | Oral delivery | Tacrolimus | P-4135F NP | DSS mice model | High drug loading and release rates. | [52] |
| UC | Passive | pH-sensitive | Oral delivery | Cur and Dex | HPMCAS-HF microencapsulated PLGA NPs | RAW 264.7, HT29-MTX, and T84 cell line model | Microcapsules have burst and sustained drug release with excellent anti-inflammatory properties. | [53] |
| UC | Passive | pH-sensitive | Oral delivery | Bud | PLGA NPs | DSS mice model | Relieves colitis and has pH-dependent drug-releasing properties. | [54] |
| UC | Passive | pH-sensitive | – | 5-ASA | Ginger-derived nanocarriers | In vitro | High encapsulation rate, outstanding stability, and excellent target specificity. | [55] |
| UC | Passive | pH-sensitive | – | 5-ASA | Polyvinyl alcohol/sodium alginate/poly(lactic acid) blend carrier | – | Controlled release of therapeutic drugs through good pH sensitivity. | [56] |
| UC | Passive | pH-sensitive | In vitro | GAR | PLGA NPs | Caco-2 cell line model | NPs can alleviate the response to inflammation by decreasing MPO activity. | [57] |
| UC | Passive | pH-sensitive | Oral delivery | 5-ASA and Cur | Sulfated chitosan/alginate composite microparticles | TNBS rats model | Releases two drugs into the target area; its therapeutic effect is better than a single-dose treatment. | [58] |
| UC | Passive | pH-sensitive | Oral delivery | Bud and prednisolone | MSNs | DSS mice model | The particles resulted in lower levels of pro-inflammatory cytokines than uncoated particles. | [59] |
| UC | Passive | pH-sensitive | Oral delivery | Cur | Curcumin coupled with Eudragit® S100 | DSS mice model, HCT116, and HT-29 cell line model | Great stability and loading rates; inhibits inflammatory response. | [60] |
| UC | Passive | pH-sensitive | Oral delivery | Prednisolone | Prednisolone wrapped by Eudragit S100 | In vitro | The nanocapsules specifically release the drug into the colon. | [61] |

(Continued)

Table I (Continued).

| IBD | Type of Targeting | Targeting Mechanism | Delivery route | Loaded Agents/Cargo | NPs Delivery System | Model | Main Results | Ref |
|-----|-------------------|---|----------------------------|-------------------------------|--|--|---|------|
| UC | Passive | pH-responsive | Oral delivery | Prednisolone | Encapsulated by succinylated ϵ -polylysine 3-aminopropyl-functionalized mesoporous silica NPs | RAW 264.7, LS 174T, and Caco-2 cell line model | MCM-NH2 is pH sensitive, allowing for targeted colonic delivery. | [62] |
| UC | Passive | pH-sensitive azo-reductase | Oral delivery | Bud | ES-Azo. Pu NPs | TNBS mice model | NPs are sensitive to enzymes and pH, allowing for sustained targeted drug release. | [63] |
| UC | Passive | pH-sensitive amylase enzyme | Oral delivery | Safranin O dye | MSNs | Rat model and, Caco-2 cell line model | Dual targeting improves the inflammatory colonic tissue specificity of the drug. | [64] |
| UC | Passive | pH-sensitive, H ₂ O ₂ -responsive | – | Rifaximin | OxiDEX NPs encapsulated in HPMCAS | Caco-2 and HT29-MTX cell line model | Highly adhesive, sensitive to H ₂ O ₂ and pH; capable of reducing the systemic adverse effect of drugs. | [65] |
| UC | Passive | pH-sensitive, Positive charges, and ROS-responsive | Oral delivery | Infliximab | Polyphenol-PEG-containing polymers NPs | DSS mice model | Higher adhesion, excellent target specificity, and biosafety | [66] |
| UC | Passive | pH-sensitive and azo-reductase enzymes | Oral delivery | Safranin O and hydrocortisone | Magnetic mesoporous silica microparticles functionalized by azo derivatives | TNBS rats model | The NPS increases the delivery efficiency of loaded drugs and improves therapeutic efficacy. | [67] |
| UC | Passive | Positive charges | Intrarectally administered | Betamethasone | Ethylcellulose nanospheres coated with polysorbate 20 | TNBS mice model, C2BBel, and RAW 264.7 cell line model | Negatively charged: the ability to target areas of inflammation with favorable adhesion. | [68] |
| UC | Passive | Positive charges | Intrarectally administered | Bud and colony-stimulating | HEP-HSA NPs | DSS mice model and RAW 264.7 cells line model | Simultaneous loading of drugs and biologics. Better anti-inflammatory effect than a single drug-loaded NP. | [69] |
| UC | Passive | Positive charges | Oral delivery | CeO ₂ NPs | CeO ₂ @MMT | DSS mice model and RAW 264.7 cells line model | CeO ₂ @MMT treats inflammation via target specificity and antioxidant action. | [70] |
| UC | Passive | Positive charges | Oral delivery | TNF- α | Polymeric NPs coupled by two different chain lengths (2 kDa and 5 kDa) of PEG and PLEG | DSS mice model, Caco-2 cells, and J774 cells lines model | PLGA-PEG2K NPs are more protective of drugs and more effective in treatment than the PLGA-PEG5K NPs. | [71] |
| UC | Passive | Positive charges | Oral delivery | Infliximab | IFX NM | TNBS mice model and HT29 cell model | Sustained release function and anti-inflammatory properties promote mucosal healing. | [72] |

(Continued)

Table 1 (Continued).

| IBD | Type of Targeting | Targeting Mechanism | Delivery route | Loaded Agents/Cargo | NPs Delivery System | Model | Main Results | Ref |
|-----|-------------------|-------------------------------|----------------------------|---------------------|---------------------------------|--|---|------|
| UC | Passive | Positive charges | – | Zingerone | Zin-SLNPs | RAW 264.7 cell line model | Negative surface charge for better adhesion; superior biosafety. | [73] |
| UC | Passive | Positive charges and esterase | Intrarectally administered | Dex | Inflammation targeting hydrogel | DSS mice and TRUC mice model, Caco2, and HT-29 cell line model | IT-hydrogel reduces systemic drug exposure, prolongs local drug release, and improves efficacy more than free Dex enemas. | [74] |

Abbreviations: ST, Spleen targeting; H₂S, H₂S donor; NLCs, nanostructured lipid carriers; SiNP, silica nanoparticles; PPNP, polymers self-assembled nano-particle; IFX, infliximab; PLGA, poly(lactic-co-glycolic acid); 5-ASA, 5-Amino salicylic acid; siRNP, silica-containing redox nanoparticles; SeM, diselenide-bridged mesoporous silica nanoparticles; AC, aminoclay-liposome-coated; EAC, Eudragit S100-liposome-coated; MSMs, mesoporous silica materials; MSs, multilayer-coated mesoporous silica; Cur, curcumin; EM, *Escherichia coli* strain Nissle 1917-(EcN) membrane; Bud, budesonide; Azo.pu, azo-polyurethane; HES, hydroxyethyl starch; Tpl, tempol; OxbCD, Oxidation-responsive b-cyclodextrin; OVA, oval-bumin; BBR, berberine; HPMCAS, hydroxypropyl methylcellulose acetate succinate; GAR, garcinol; MSNs, mesoporous silica nanoparticles; OxiDEX, oxidation-sensitive dextran; TNF- α , tumor necrosis factor- α ; PEG, polyethylene glycol; HEP, heparin; HAS, human serum albumin; NP, nanopoly-plex; SLNPs, solid lipid nanoparticles; MMT, montmorillonite.

Table 2 The Active Targeting and Functional Effects of Nanoformulations for IBD Treatment

| IBD | Type of Targeting | Targeting Mechanism | Delivery route | Loaded Agents/Cargo | Nps Delivery System | Model | Main Results | Ref |
|-----|-------------------|---------------------|----------------------------|---------------------|-----------------------|---|--|------|
| UC | Active | Mannose receptors | Oral delivery | Cur | Cur–AceKGM NPs | RAW264.7 cells lines model | Cur–AceKGM NPs are more targeted and have superior therapeutic efficacy compared to oral doses of free Cur. | [75] |
| UC | Active | SRAI | Oral delivery | SOD | ARC-SOD | J774 A.1 cells and Caco-2 cells lines model | Potent antioxidant and anti-inflammatory properties promote macrophage endocytosis of drug loading. | [76] |
| UC | Active | Folate receptors | Intrarectally administered | SOD | SNP-FA | TNBS mice model and RAW264.7 cells line model | Good stability and biological activity; capable of targeted colonic delivery to reduce drug side effects | [77] |
| UC | Active | CD44 receptors | – | Bud | HANPs | Caco-2 and NIH3T3 cells lines model | Excellent biosafety; better ability to inhibit inflammatory factors than free drugs | [78] |
| UC | Active | CCR5 receptor | Oral delivery | Piceatannol | Piceatannol–PLGA–CCL4 | UC patients, DSS mice model and Caco-2 cells line model | Excellent biocompatibility; inhibits the expression of pro-inflammatory genes; regulates the balance of intestinal flora | [79] |

(Continued)

Table 2 (Continued).

| IBD | Type of Targeting | Targeting Mechanism | Delivery route | Loaded Agents/Cargo | Nps Delivery System | Model | Main Results | Ref |
|-----|-------------------|--|----------------|------------------------|------------------------|---|---|------|
| UC | Active | Cytoplasmic/membrane proteins of the intestinal mucosa | Oral delivery | – | GDNPs 2 | DSS mice model and RAW264.7 cells lines model | GDNPs 2 are natural NPs that reduce the production of pro-inflammatory factors and improve the treatment of colitis | [80] |
| UC | Active | Mannose receptors | Oral delivery | Apremilast | CDs.EP/Man/Meth.Cs NPs | Caco-2 and RAW 264.7 cells line model | CDs.EP/Man/Meth.Cs NPs enable specific accumulation of drugs at the site of inflammation allowing uptake by macrophages | [81] |
| UC | Active | Mannose receptors | Oral delivery | Anti-TNF-a nucleotides | cKGM and ASO | DSS mice, CT-26 cells and RAW 264.7 cells lines model | cKGM and ASO can transfer ASO to colonic macrophages and reduce the symptoms of colitis by decreasing TNF-a levels | [82] |
| UC | Active | Mannose receptors | – | Bud | Mn-NLCs | Oxazolone rat model and J774A.1 cells line model | Excellent encapsulation rate; great biocompatibility; capable of reducing the level of inflammatory factors | [83] |
| UC | Active | CAR1 | Oral delivery | Inf | INF/LMSN@GE | DSS mice model | Transmission stability; colonic targeting specificity; anti-inflammatory effects | [84] |
| UC | Active | SRA1 | Oral delivery | Dex | NAC-Dex | THP-1 cells and Caco-2 cells lines model | NAC-Dex reduces the release of inflammatory factors and the production of reactive oxygen species; repairs the intestinal barrier | [85] |
| UC | Active | SRA1 | – | Dex | SAN-Dex | J774A.1 cells and Caco-2 cells lines model | Compared to free Dex, SAN-Dex is more effective in reducing inflammatory factors | [86] |
| UC | Active | Scavenger receptors (SRs) | Oral delivery | Bud | hMnO2 NPs. | DSS mice model and RAW 264.7 cells line model | NPs carriers with antioxidant function synergize with loaded drugs for the treatment of colitis | [87] |

(Continued)

Table 2 (Continued).

| IBD | Type of Targeting | Targeting Mechanism | Delivery route | Loaded Agents/ Cargo | Nps Delivery System | Model | Main Results | Ref |
|-----|-------------------|--|----------------|----------------------|---------------------|---|---|------|
| UC | Active | Adhesion molecule receptors and proinflammatory cytokine receptors | Oral delivery | PDA | PDA@mCRAMP@MM | DSS mice model and RAW264.7 cells line model | Inflammatory targeting; anti-inflammatory effect through regulation of immune function; regulation of intestinal flora | [88] |
| UC | Active | Folate-targeted | Oral delivery | Resveratro | PLGA-FA-RSV | TNBS rats model and Caco-2 cells line model | PLGA-FA-RSV enhances the targeted transport of the drug with excellent therapeutic efficacy | [89] |
| UC | Active | Galactose receptors | Oral delivery | TNF- α siRNA | PLA-PEG | DSS mice model, RAW264.7 cells and Caco-2 cells lines model | Improved drug utilization and delivery efficiency; biodegradability; anti-inflammatory effects through inhibition of inflammatory factor production | [90] |
| UC | Active | CD44 receptors | Oral delivery | OPN | BSA/OPN-NPs | DSS mice model | Exerts anti-inflammatory effects by inhibiting MPO and inflammatory factor levels | [91] |
| UC | Active | CD44 receptors | Oral delivery | Bilirubin | HABN | DSS mice model and J774A.1 cells line model | Greater target specificity of HABN compared to NPs without HA function painting | [92] |
| UC | Active | CD44 receptors | Oral delivery | Cur | Cur-HA NPs | DSS mice model and HT-29 cells line model | Improve intestinal mucosal barrier; regulate intestinal flora diversity | [93] |
| UC | Active | Integrin α v | Oral delivery | PA | cRGD-PA-SF NPs | DSS mice, Caco-2 and RAW 264.7 cell line | cRGD-PASFNs can alleviate inflammation and improve the colonic barrier with good therapeutic effects. | [94] |

Abbreviations: AceKGM, acetylated konjac glucomannan; CDs.ER, carbon dots functionalized Enteromorpha polysaccharide; Man, mannose; Meth.Cs, methionine functionalized Chitosan; cKGM, cationic konjac glucomannan; ASO, antisense nucleotide; Mn, mannosylated nanostructured; LMSN, large mesoporous silicon nanoparticle; GE, ginger-derived exosome; ARC, archaeolipids; SOD, superoxide dismutase; NAC, nanostructured archaeolipid carriers; Dex, dexamethasone; SAN, solid archaeolipid nanoparticles; hMnO₂, hollow mesoporous manganese dioxide; PDA, polydopamine; mCRAMP, mouse cathelicidin-related antimicrobial peptide; SNP, lipid-polymer hybrid nanoparticles; FA, folic acid; RSV, resveratrol; mCRAMP, mouse cathelicidin-related antimicrobial peptide; MM, macrophage membrane; PLA, poly (lactic acid); PEG, poly (ethylene glycol); OPN, osteopontin; BSA, bovine serum albumin; HA, hyaluronic acid; HABN, hyaluronic acid-bilirubin nanomedicine; CCL4, chemokine C-C motif ligand 4.

Lamprecht et al¹⁰⁷ showed the advantageous impacts of nanoscale particle size for UC treatment by comparing the bioadhesive capabilities of fluorescent polystyrene particles measuring 10 μ m, 1 μ m, and 100 nm. When compared to a healthy colon, it was discovered that 100 nm particles adhered to an inflammatory colon in rats under oral

Table 3 The Hybrid Targeting and Functional Effects of Nanoformulations for IBD Treatment

| IBD | Type of Targeting | Targeting Mechanism | Delivery route | Loaded Agents/ Cargo | NSPs delivery system | Model | Main results | Ref |
|-----|-------------------|------------------------------------|----------------|----------------------|----------------------|--|---|-------|
| UC | Passive, active | pH-sensitive, mannose receptor | Oral delivery | cKGM and ASO | GelMA | DSS mice model, CT-26 cells, and RAW 264.7 cells lines model | The microspheres can target macrophages, thereby reducing inflammation and drug toxicity. | [95] |
| UC | Passive, active | ROS-responsive CD44 receptor | Oral delivery | Thioketa | Ra@TH | DSS mice model, RAW 264.7 and HT-29 cells | The Ra@TH system enables the delivery of rapamycin to sites of colitis-specific inflammation through the active targeting of the CD44 receptor. This allows for the controlled release of rapamycin at ROS-sensitive lesions. | [96] |
| UC | Passive, active | ROS-responsive CD44 receptor | Oral delivery | Infliximab | IFXSS@HA or IFXTK@HA | TNBS mice model and HT 29 cell line model | The nanocomposite has a high drug-loading capacity and high specificity, which reduces systemic exposure and provides better therapeutic results than intravenous drugs. | [97] |
| UC | Passive active | Positive charges, mannose receptor | – | Man-NPs | CDs/Man-NPs | DSS mice model, RAW 264.7, and Caco-2 cell line model | CDs/Man-NPs target macrophages and are internalized by absorption, reduce adverse effects of drugs, and improve drug utilization. | [98] |
| UC | Passive active | pH-sensitive CD44 receptor | Oral delivery | SK | ES100/HA/CS NPs | TNBS mice model and RAW 264.7 cell line model | ES100/HA/CS NPs exert therapeutic effects by reducing ROS production and inhibiting the release of inflammatory factors. | [99] |
| UC | Passive active | pH-sensitive CD44 receptor | Oral delivery | Methotrexate | HA-CS/ES100/PLGA NPs | TNBS mice model RAW 264.7 cell line model | HA-CS/ES100/PLGA NPs are specific; they alleviate intestinal inflammation by reducing inflammatory cell infiltration and decreasing intestinal mucosal damage. | [100] |

Abbreviations: GelMA, gelatin methacryloyl; SK, shikonin; CS, chitosan; ES100, Eudragit S100; MTX, methotrexate; CDs, carbon dots; Man, mannosylated; PA, patchouli alcohol; cRGD, cyclo RGD peptide; and SF, silk fibroin.

administration compared to a healthy colon. Furthermore, the faster the drug was absorbed and the greater the therapeutic effect, the smaller the particle size.

Solid lipid NPs (SLNs) have become an appealing drug delivery mechanism among the available nanocarriers.¹⁰⁸ Compared to other lipid NPs (liposomes, etc.), SLNs have superior stability, biocompatibility, and degradability in the gastrointestinal tract, along with the capacity to influence immune responses and anti-inflammatory properties.^{109,110} Beloqui et al developed nanostructured lipid carriers (BDS-NLC) containing budesonide (BDS) with an average diameter of approximately 200 nm.²⁶ Research conducted *in vitro* showed that BDS-NLC could encapsulate up to 95% of the drug and prolong its half-life in the colon. Similarly, it produced therapeutic benefits comparable to those of healthy control

Table 4 The Effectiveness and Limitations of Different Types of Drug Delivery Systems for the Treatment of IBD

| Type of Targeting | Targeting Mechanism | Effectiveness | Limitations |
|-------------------|---------------------|--|--|
| Passive targeting | EPR effect | The NPs developed based on the EPR effect accumulate at the site of inflammation, prolonging the residence time in the inflamed intestinal area and avoiding the rapid clearance of the carrier. It could reduce the adverse effects of the loaded drug and improve the utilisation of the drug compared to the free drug. | The EPR effect only promotes the accumulation of DDSs in colitis tissues, whereas inefficient target cell uptake and insufficient intracellular drug release limit the therapeutic efficacy of anti-inflammatory drugs. Moreover, the instability of NPs drugs may increase during the preparation process or when the formulation is changed. |
| | Enzymes | Enzyme-targeted NPs with a favourable biosafety profile can selectively accumulate in inflamed tissues and achieve therapeutic efficacy through delayed release. Some NPs drugs protect the integrity of the intestinal barrier and enhance intestinal homeostasis. | Shorter gastrointestinal transit times may reduce drug release under disease conditions. |
| | ROS-responsive | The drug release of ROS-dependent NPs is efficient and less toxic, while its synergy of anti-inflammatory and antioxidant effects can attenuate the inflammatory damage in the colonic mucosa. | Oxidative stress may not be the main causative agent of the disease. If the loaded drug was released in bursts, its excessively rapid release rate may make the duration of the drug quite short. |
| | pH-sensitive | The pH-dependent delivery system protects the drug from gastrointestinal disorders, resists unfavourable gastrointestinal conditions and reduces premature drug release. | The design of drug delivery systems based solely on the pH of the gastrointestinal tract is unreliable due to differences of pH between individuals and the variation of pH in the intestinal lumen caused by disease states. It can result in incomplete or premature drug release from the colonic target site. |
| | Positive charge | The positive charge-targeted NPs promote cellular uptake and drug release, allowing better drug contact with mucosal surfaces and increasing targeting and retention of the drug delivery system. | The charge-dependent nanoparticles have the potential to bind to other charge-modified substances during gastrointestinal transport. There are fewer studies on charge-dependent delivery system loading and further experimental exploration is needed. |
| Active targeting | / | Actively targeted drugs are highly specific and selective for the site of targeting, reducing drug redistribution in healthy tissues, improving therapeutic efficacy and reducing systemic adverse events of the drug. | Further in vivo studies are needed to assess the efficacy and stability of different targeting ligands and formulations in animal models of colitis. |
| Hybrid targeting | / | Integrated systems with different release triggering mechanisms help overcome pathophysiological variability more than single systems. Passive targeting reduces the non-specific uptake of drug carriers at non-target sites and improves the targeting of active targeting systems. Active targeting promotes specificity of the drug system. Thus hybrid targeting systems enable precise targeting of drug-carrying nanoparticles and further reduce their side effects. | The release triggering mechanisms of different hybrid-targeted nanoparticles still need to be further refined. And the differences between animal models and human patients should be fully recognised, which requires more experimental data models to validate the biosafety and efficacy of the newly developed NPs. |

colon tissue by lowering the levels of myeloperoxidase (MPO), interleukin (IL) IL-1 β , and tumor necrosis factor (TNF) TNF- α (Figure 2).

Furthermore, protamine has been used to develop stable nanocapsules.¹¹¹ Jakubiak et al encapsulated cyclosporine A in protamine-coated nanocapsules.²⁷ The average particle size of these NPs was 160–180 nm. Although this nanocapsule showed




Figure 1 Strategies for inflammatory bowel disease treatment using nanoparticle-based drug delivery systems. Nanoparticles specifically target inflammatory colonic epithelial cells based on enhanced permeability and retention effects (A), specific enzyme levels (B), reactive oxygen species (ROS) levels (C), specific pH levels (D), electrostatic interactions (E), and ligand-receptor interactions (F).




Figure 2 The expression of myeloperoxidase activity (A), TNF- α (B), and IL-1 β (C) was significantly decreased in the colon of mice treated with budesonide-nanostructured lipid carriers compared to the control group. Reprinted from *Int J Pharm*, volume 454(2), Belouqui A, Coco R, Alhouayek M, et al. Budesonide-loaded nanostructured lipid carriers reduce inflammation in murine DSS-induced colitis. 775–783, Copyright 2013, with permission from Elsevier.²⁶

good stability against trypsin in simulated trials, predicting its stability and drug release in vivo is challenging. In vitro experiments demonstrated that these NPs were superior to commercial agents in their ability to decrease IL-2 levels.

The treatment of experimental colitis with celecoxib (CXB) has demonstrated significant efficacy.^{112,113} A formulation of CXB nanomixed micelles (NMMs) was developed to investigate the adverse effects of colon-targeted agents to reduce CXB. The NMMs were then integrated into a novel pulsatile capsule with an average particle size <290 nm.²⁸ The capsule could be released in vitro in 88.35% of cases if the capsule is designed to target the colonic site. Furthermore, it demonstrates superior defense against acetic acid-induced experimental colitis models compared to regular capsules.

Ali et al designed NPs that target inflammatory colonic mucosa by inserting budesonide into poly(l-propylene-glycoside lactone) (PLGA) NPs with an average particle size of 200 nm.²⁹ Fluorescence analysis showed that while the NPs could be dispersed throughout the digestive tract in the colonic tissues of healthy mice, the particles appeared more at the inflamed site in inflamed mice. It is also important to note that the drug displayed a biphasic release pattern in vitro, releasing rapid at first, then slowly and continuously after that. They suggest that the initial rapid release could be because the drug molecules are just attached to the surface of the NPs rather than fully encapsulated.

Protein NPs have gathered attention recently because of their excellent biocompatibility and advantages in biodegradability.^{114,115} Covalently binding 5-aminosalicylic acid to hemoglobin produced the NPs with a diameter of

about 220 nm.³⁰ Only 8% of the drug was absorbed and released within 4 h following the vitro simulation test. Data from their vivo trials also showed that 85% of the NPs could reach the colon and release the drug. This suggests that the system has outstanding stability and is able to slow drug release in the stomach.

The lack of polysaccharide-degrading enzymes in the human body may prevent the natural polysaccharide found in sawdust gum from being degraded in the upper gastrointestinal tract.¹¹⁶ However, the microflora enzymes present in the colorectum can degrade it to produce fatty acids.^{117,118} A regimen with a mean particle size of 228 nm was shown to be optimized by Amaldoss et al after developing tamarind gum NPs loaded with rifaximin.³¹ Compared to the control group, the NPs effectively lowered colonic inflammation. Furthermore, studies conducted on patients with IBD have demonstrated a significant increase in platelet counts in the literature.¹¹⁹ However, they performed testing studies and discovered that neither the treatment group nor the blood fractions had significantly higher platelet levels.

Additionally, passive targeting based on the EPR effect has been observed by others. This could lead to some passive accumulation of NPs at the inflammation site and decrease the loaded drug's adverse effects.^{32–34} However, this single effect-based approach to drug delivery is not ideal. Furthermore, during the synthesis of NPs, the drug encapsulation rate may be satisfactory. However, variations in the preparation processes or formulations may cause NPs to have unstable properties, making it challenging to achieve acceptable outcomes. Furthermore, it is unlikely that the interactions of NPs with the tissues or cells in the inflamed colon will be the primary means of targeting the colon.³⁴

Targeting Based on Enzymes

The gastrointestinal tract contains various enzymes, including lysozyme, azo reductase, esterases, sphingomyelinase, etc.^{11,120} Furthermore, the enzyme secretion of patients with IBD significantly differed from that of healthy individuals. These digestive enzymes quickly degrade drugs, which reduces their therapeutic efficacy. The enzyme reaction pattern depends on certain enzymes to catalyze chemical reactions. The drug is released at the lesion site by surface-modified DDSs, which use the enzymes as stimuli to cause their degradation or morphological transformation (Figure 1B).^{35–41}

Intestinal pathogens cause aberrant lysozyme secretion in the colon by interfering with cellular function.^{121,122} Li et al developed a lysozyme-triggered chitosan polyaniline microgels loaded with vancomycin (VM).³⁵ The biodegradation of the microgel was triggered by lysozyme, which also cleaved the glycosidic bond and released VM (Figure 3). According to an in vitro test, the drug was released in the inflammatory colon within 30 min, up to 76.9%. The microgel system inhibited *S. aureus* at the same concentration as the control without lysozyme. The Caco-2 cell line had an excellent biosafety profile with a cell survival rate of >86.1% in experiments.

Moreover, azo reductase is the most widely used enzyme for azo polymer adhesion, hydrogels, coatings, etc.¹²³ Additionally, the researchers developed multilayer-coated mesoporous silica (MSs), which activates azo reductase generated by intestinal microorganisms to release loaded drugs.³⁶ According to the test findings, mice in the oral-free drug group had a drug concentration 35 times lower at the colonic site than the mice. Notably, aryl hydrocarbon receptor activation by tryptophan-functionalized chitosan can protect the integrity of the intestinal barrier and enhance intestinal homeostasis when it is transformed into metabolites by intestinal flora.

Silica as a drug carrier NP in biomedical applications has advanced significantly. Researchers have developed a pre-drug system to treat colitis by loading 5-aminosalicylic acid onto silica NPs (SiNP).³⁷ Studies revealed that mice in the SiNP group accumulated six times as much drug in the inflamed tissue as in the control group, significantly decreasing the drug dosage needed for treatment. Experiments conducted on mice have demonstrated that the nanodrug selectively accumulates in inflamed tissues and prolongs the presentation duration to achieve a therapeutic impact with a delayed release. Although esterases can gradually initiate the catabolic conversion of precursor drugs, as demonstrated by drug release experiments, further in vivo research is required to understand this phenomenon fully.

Furthermore, natural polyphenols have drawn much attention as safe compounds with free radical scavenging and antioxidant properties.^{124,125} Consequently, researchers designed a DDSs encapsulated with dexamethasone (DEX) by self-assembling polyphenols (tannins) and polymers.³⁸ When esterase is present at a concentration of 30 U/mL, up to 62% of DEX is released. According to pharmacofluorescence imaging, the fluorescence intensity of the inflamed mouse colon was shown to be four times higher than that of the healthy colon. Furthermore, PPNP-DEX had a better therapeutic impact on colitis-affected mice than PPNP and free DEX. Research has shown that non-degradable polyethylene glycol




Figure 3 Lysozyme-triggered release of vancomycin from chitosan microgels for treating inflammatory bowel disease. **(A)** Schematic representation and mechanism of action of lysozyme-triggered nanoparticles. **(B)** Determination of Caco-2 cell activity in various treatment groups. **(C)** Inhibitory effect of N-CH-PANI@VM MGs on *Staphylococcus aureus* in various environments. **(D)** Cumulative release of lysozyme-induced VM in various simulated environments. Adapted from *J Adv Res*, volume 43, Li X, Hetjens L, Wolter N, et al. Charge-reversible and biodegradable chitosan-based microgels for lysozyme-triggered release of vancomycin. 87–96, Copyright 2023, with permission from Elsevier.³⁵

(PEG) compounds can produce anti-polyethylene glycol antibodies in vivo, making PEG drugs biologically inactive.¹²⁶ However, they discovered little impact of anti-PEG antibodies on oral PEG drugs by fluorescence imaging, contrary to the report.

Sphingolipid liposomes were also used to develop the NPs,³⁹ and ICG was fluorescently labeled because sphingomyelinase is present outside of cells during cellular stress.¹²⁷ The results of the experiment showed that liposomes could be taken up by both epithelial cells and macrophages, thus accomplishing drug delivery. In the inflammatory colon, macrophages produced higher sphingomyelinase activity and greater drug phagocytosis than epithelial cells.

Furthermore, materials made of naturally occurring chemicals offer good biosafety and biocompatibility. Xu et al produced NP formulations with anti-inflammatory and antioxidant properties by packing DEX within curcumin and hydroxyethyl starch micelles.⁴² In vitro release assays demonstrated that the negatively charged outer surface of NPs aided in their binding to inflammatory colon cells, and the α -amylase increased the drug release rate. NPs decreased the severity of inflammatory lesions and improved the effectiveness of free DEX compared to the untreated group.

Targeting Based on ROS

Free radicals, such as superoxide (O_2^-) and $^{\cdot}OH$, and non-free radicals, like singlet oxygen (1O_2) and hydrogen peroxide (H_2O_2), make up the majority of ROS.^{128,129} Bowel inflammation is caused by pro-inflammatory mediators, including TNF- α and IL-1, produced when ROS triggers the NF- κ B signaling cascade.¹³⁰ Oxidative damage in the colon is caused by an excess of ROS and an imbalance of antioxidants in the intestinal mucosa of patients with IBD.^{129,131,132} Activated phagocytes and leukocytes at the site of colitis are the primary source of the increased production of ROS.¹³³ According to a study, patients with IBD had 10- to 100-fold higher ROS concentrations in intestinal inflammation than healthy individuals.^{134,135} Redox-responsive DDSs have gained attention from researchers to improve targeted drug delivery in inflamed intestinal areas (Figure 1C).^{43–47}

Drug-drug coupling systems, with their high drug loading and minimal side effects, have been suggested as a novel approach. Li et al developed spherical nanostructures by self-assembling ROS-sensitive aromatized thione linkers with the anti-inflammatory drug budesonide and the antioxidant tempol (Figure 4).⁴³ Interestingly, the drug loading of the NPs was more significant (41% and 16%) than the loading of the two drugs in the PLGA NPs (6% and 3%). In the simulated environment experiment, the ROS-dependent release pattern led to nearly full release (99% and 98%) of these NPs for both drugs. Conversely, only 44% and 18% of the drug was released from PLGA NPs. The concurrent release of the two drugs allowed for the synergistic anti-inflammatory and antioxidant effects.

Additionally, superoxide dismutase (SOD) breaks down superoxide to form hydrogen peroxide, which catalase then breaks down into water. Zhang et al produced NPs (Tpl/OxbCD NP) by encapsulating the free radical scavenger Tempol (Tpl) in oxidation-responsive β -cyclodextrin, which releases cargo molecules by scavenging ROS components. According to drug imaging, OxbCD NPs had a higher targeting effectiveness than control PLGA NPs and accumulated 2.5 times more fluorescence intensity in mouse colon tissue than in normal mice. The oral Tpl/OxbCD NPs group showed a significant reduction in symptoms in three mice colitis models, with more efficacy than the free radical scavenger Tpl and -based control nanomedicine.⁴⁴

In addition, IBD makes it easier for pathogens, such as intestinal bacteria, to enter the bloodstream and invade other organs. The goal of the design was a drug delivery system that scavenges ROS from the inflamed colon while also delivering antioxidant drugs to the bloodstream to reduce systemic inflammation. Researchers have developed silica-containing redox NPs that can scavenge ROS when loaded with silymarin.⁴⁵ According to the findings of in vivo experiments conducted on mice, the blood uptake of silymarin was significantly increased by the antioxidant carrier (siRNP). Additionally, the damage to the inflamed colonic mucosa was decreased considerably by the synergistic antioxidant effect of the drug and carrier.

Targeting Based on pH Levels

In contrast to the colon and rectum, which have pH values between 7.1 and 7.5, the stomach has an acidic pH.¹³⁶ Drug protection from gastrointestinal conditions and delayed drug release in acidic pH conditions can be achieved by NPs with a pH-sensitive design (Figure 1D). Scientists have developed drugs that are unique to the colon due to variations in the pH of the various gastrointestinal tract organs. Several pH-sensitive nanostructures, such as nanospheres, nanocapsules, and nano-polymers encapsulating other materials, have been developed. Additionally, colon-targeted drug delivery systems were designed using pH-dependent polymers, including methacrylic acid and methyl methacrylate (Eudragit[®] S 100, Eudragit[®] L, Eudragit[®] FS and Eudragit[®] P4135 F),¹³⁷ hydroxypropyl methyl phthalate cellulose, and few other polymers.^{14,48–62} Eudragit[®] polymer is one of the most widely used synthetic copolymers for colonic drug delivery.¹³⁸

The ionization of carboxyl functional groups makes the Eudragit[®] s100 resistant to invasion of the upper gastrointestinal tract, and it becomes soluble at pH >7.^{139,140} Qelliny et al⁴⁸ synthesized NPs were loaded with budesonide, and their surface was coated with pH-sensitive Eudragit[®] s100. Studies conducted in vitro show that up to 72% of its maximum short-term cumulative release occurs at pH 7.4. Additionally, studies conducted on animals suggested that it had a more significant therapeutic effect on UC than the drug suspension in its free form.

Furthermore, Zhang et al developed hybrid drug delivery systems by encapsulating PLGA NPs loaded with berberine within an Eudragit[®] FS 30D matrix that has already been pre-encapsulated with berberine (Figure 5).⁴⁹ This pH-sensitive system immediately releases the drug-loaded NPs and berberine upon reaching the colon for lysis. The PLGA NPs are then absorbed by the colonic mucosa and gradually breakdown to maintain the sustained release of the drug. This pH-




Figure 4 Sensitive reactive oxygen species-responsive B-ATK-T nanoparticles (NP) for treating irritable bowel disease. **(A)** The synthetic process of B-ATK-T. **(B)** Hydrolysis rate of B-ATK-T NP at various concentrations of hydrogen peroxide (H_2O_2). The release profiles of 9-fluorenone **(C)**, budesonide **(D)**, and tempol **(E)** from B-ATK-T NP at varying concentrations of H_2O_2 concentrations. Reprinted from *J Control Release*, volume 316, Li S, Xie A, Li H, et al. A self-assembled, ROS-responsive Janus-prodrug for targeted therapy of inflammatory bowel disease. 66–78, copyright 2019, with permission from Elsevier.⁴³




Figure 5 The novel nano-delivery system MNEHDS for treating irritable bowel disease. **(A)** The manufacturing process of MNEHDS. **(B)** Berberine (BBR) drug release rates in various simulated environments. The changes in BBR concentrations were investigated at various intervals in the plasma **(C)**, colon **(D)**, and feces **(E)**. Reprinted from Zhang L, Li M, Zhang G, et al. Micro- and nanoencapsulated hybrid delivery system (MNEHDS): a novel approach for colon-targeted oral delivery of berberine. *Mol Pharmaceut.* 2021;18(4):1573–1581. Copyright © 2021 American Chemical Society.⁴⁹

sensitive nanosystem accomplishes drug release into the tissue instantly and continuously. It promotes better therapeutic efficacy and patient compliance by lowering the amount of drug required and the frequency of administration.

The process of creating polymer NPs involves grafting polyacrylamide (PAAm) onto the backbone of xanthan gum (XG).⁵⁰ Upon additional NP hydrolysis, the PAAm amide functional group is transformed into a carboxylic acid (-COOH) group, creating a pH-sensitive copolymer.¹⁴¹ Moreover, coliform bacteria can activate XG. Therefore, the NPs are very selective for colonic targeting. At a pH of 6.8, 3 h were needed to release approximately 65% of the drug. In vitro tests on rats

have revealed that the drug release rate is <15% with an acidic pH. However, within 8 h, the drug release rate may reach 100% if the pH of the solution is increased to 6.8 and intestinal contents are added.

Additionally, IL-1 receptor antagonist (IL-1Ra)-containing alginate/chitosan microcapsules were prepared.⁵¹ Chitosan is a cationic polysaccharide.¹⁴² The electrostatic interaction between the two is diminished in weak alkaline solutions because chitosan has a lower positive charge than alginate. This lets alginate absorb water and swell in an inflammatory colon environment, releasing the drug.¹⁴³ Furthermore, the microcapsules acquired an ultimate cumulative release rate of 86.2% *in vitro*. The microcapsules decreased the dose-induced colitis in mice, partially allowing the drug to accumulate in the colon.

Meissner et al developed a pH-sensitive Eudragit P-4135F polymer for colonic delivery of drug-loaded NPs to increase drug delivery efficiency and tolerability.⁵² The polymer can break down and release the drug at pH >7.2. *In vitro* tests demonstrated that after 30 min, 100% of the loaded drug release at pH 7.4 could be achieved. Moreover, the oral NP formulation outperformed the free oral drug, although it was less effective in alleviating experimental colitis than subcutaneous administration.

The pH-dependent delivery mechanism may keep the drugs from dispersing before they reach the colon site. However, patients with IBD have a more acidic pH range in their colons,¹³⁶ which leads to partial drug release from the target site.¹⁴⁴ Researchers have created pH-dependent systems with alternative drug delivery systems, such as ROS-dependent or enzyme-triggered systems, to overcome the limitations of single pH-dependent DDSs.^{63–67}

Naeem et al developed a pH- and azo reductase-sensitive azo polyurethane and Eudragit[®] S100 NPs.⁶³ Compared to single-trigger ES NPs, the NPs provide superior therapeutic efficacy by preventing a sudden release of the drug in the ileum and delivering an adequate amount to the inflamed colon. Budesonide is then sustained and released by an enzymatic reaction compared to single-trigger ES NPs. Pilot tests have demonstrated that the NPs are more stable than the pH-dependent type alone, preventing early drug release and enabling targeted colonic drug delivery.

The researchers developed mesoporous silica NPs, coated them with hydrolyzed starch, and placed them inside capsules containing Eudragit[®] FS 30D.⁶⁴ The nanosystem made it possible to alleviate the adverse effects of the drug and increase drug concentration at the colonic inflammatory site. Mesoporous silica NPs are released from the nanocapsules at colonic pH and are endocytically transported into colon cells after amylase stimulation.

The researchers developed an antioxidant-responsive dextrose (OxiDEX) NPs loaded with rifaximin.⁶⁵ The pH-responsive polymer hydroxypropyl methylcellulose acetate succinate was then used to encapsulate the NPs in chitosan surfaces. A pH- and ROS-responsive nanodelivery system was formed. Upon entering the colon and passing the acidic environment of the stomach, the NPs will release RIF in response to a trigger that increases ROS levels. *In vitro* experiments have demonstrated that the system can initiate the release mechanism at intestinal pH (6.8) and that, in the presence of H₂O₂, NPs can release >60% of the drug.

In addition, Wang et al developed infliximab-loaded polyphenol-containing PEG polymer self-assembled NPs.⁶⁶ In the stomach, the NPs aggregated into large-sized NPs. Then, at neutral pH in the colon, they reversibly transformed into small-sized negatively charged NPs (~100 nm). The antibody drug is then released from the NPs when they bind to the inflammatory colonic site through charge interactions and are impacted by high ROS concentrations in the mucosa. The favorable colonic targeting specificity and excellent therapeutic efficacy of the NPs were demonstrated *in vivo* in mice with colitis.

Targeting Based on Positive Charge

Surface-negatively charged DDSs has a high molecular target in the form of the positively charged protein (transferrin), which is overexpressed on the inflamed epithelial surface of IBD.¹⁴⁵ Negatively charged particles exhibit preferential adherence to injured sections of the colon through electrostatic interactions with these proteins (Figure 1E).^{68–73}

Surfactants can impact the targeting efficiency of NPs. The NPs with negatively charged surfaces were created using polysorbate 20 as a surfactant.⁶⁸ In 30 min, the colonic site may release 80% of the loaded drug. The same NPs interacted two to three times more with macrophages (RAW 264.7 cells) than with enterocytes (C2BBel cells), which is an interesting aspect that implies a simple cell line is not a sufficient model of inflamed tissue *in vivo*.

Furthermore, heparin has a significant negative charge on the outer surface. Zhang et al developed NPs targeting inflammatory colon (HEP-HSA NPs) that use the electrostatic interactions at the region of intestinal inflammation to load both biological agents and small molecule drugs.⁶⁹ *In vitro* assays revealed that the NPs had a more potent anti-

inflammatory impact than NPs loaded with a single drug. Notably, it was discovered that there was a negative correlation between the diameter of HEP-HSA NPs and mucosal binding, with larger NPs preferentially binding to inflamed mucosa. And the investigation indicates that the smaller particle-size NPs enter the submucosa deeper.

Active Targeting

Drug distribution was improved in the inflamed areas of the colon by the EPR effect, which was facilitated by the particle size and surface physicochemical properties of NPs. However, this only promoted the accumulation of DDSs in colitis tissues. Insufficient target cell absorption efficiency and low intracellular drug release restrict anti-inflammatory drug therapeutic efficacy. Therefore, developing nanocarriers capable of actively targeting inflammatory cells may enable more precise targeting of colonic disease and minimize adverse side effects more effectively.

Specific antigens or receptors, such as the mannose, scavenger, folate, CD44, and chemokine receptors, are significantly overexpressed by epithelial cells and activated macrophages during the development of IBD. The interaction between particular receptors expressed at the diseased site and targeting ligands on the surface of the vector has increased targeting specificity. It also increases the degree of endocytosis and the bioadhesion of drug agents to particular cells (Figure 1F).^{75–94}

The mannose receptor is overexpressed explicitly on the surface of macrophages at the site of inflammation.¹⁴⁶ Upon contact with this receptor system, NPs are rapidly internalized through receptor-mediated endocytosis, resulting in targeted drug delivery. Wang et al developed a naturally occurring polysaccharide-based NP that targets binding to macrophage mannose receptors.⁷⁵ According to the experimental results, NPs exhibited 81% drug release within 48 h, and the MPO levels of the mice were decreased. The NPs offer sustained release of curcumin and effective therapeutic outcomes compared to oral free curcumin administration (Figure 6).

Phosphatidylglycerophosphate methyl ester (PGP-Me) is a ligand for the scavenger receptor, which is highly expressed in macrophages and dendritic cells.¹⁴⁷ SOD was delivered via nanovesicles containing PGP-Me, which also could promote endocytosis of the drug carried by macrophages.⁷⁶ The study showed that mouse macrophages took up the nanosystem 6.4 times more than liposomal NPs. The activity of the enzymes it contains remained unchanged when exposed to conditions similar to oral administration, compared to the control group.

Furthermore, Le et al developed NPs functionalized on folic acid surfaces that were loaded with antioxidant enzymes.⁷⁷ They next evaluated a mechanism dependent on cellular endocytosis mediated by the folic acid receptor. Its PEG coating keeps antioxidant enzymes from breaking down. In vitro, cellular uptake tests demonstrated that the NPs could be absorbed by macrophages and epithelial cells and displayed a powerful solid fluorescent signal compared to controls. Moreover, the results of in vivo tests showed that intrarectal administration significantly decreased colitis symptoms in mice models by downregulating the production of pro-inflammatory cytokines.

Moreover, hyaluronic acid is a primary gastrointestinal mucosal epithelial extracellular matrix component, enabling interaction with overexpressed CD44 receptors.^{148,149} Budesonide-loaded hyaluronic acid nanosystems (HANPs) were designed.⁷⁸ Compared to uncoated nanocomplexes, the HANPs enhanced cell adhesion and uptake in vitro experiments. Moreover, when HANPs and the exact dosage of free drugs were used in inflammatory cell models, HANPs showed higher anti-inflammatory effects on the secretion of inflammatory factors.

Chemokine receptor (CCR5) can be expressed on the macrophage surface.¹⁵⁰ Gong et al combined the chemokine ligand CCL4 with PLGA NPs to allow it to bind to the macrophage surface receptor CCR5, significantly improving the targeting ability of the drug.⁷⁹ Fluorescence staining showed that colonic macrophages could take up the NPs. The NPs not only improved the dysbiosis of the intestinal flora, but also promoted the repair of the intestinal barrier function by loading spleen tyrosine kinase inhibitors and decreasing the production of cytokines and chemokines.

Overall, the active targeting of ligands attached to the surface of nanodelivery systems is a promising strategy for treating IBD. Targeted ligands and targeted receptors expressed at inflammatory areas may improve the bioadhesion of drug formulations to particular cells and increase the degree of drug endocytosis. However, further in vivo research is required to evaluate the effectiveness of different strategies.




Figure 6 AceKGM nanoparticles for the treatment of irritable bowel disease. The percentage change in mice from various treatment groups body weight (A), Disease Activity Index score (B), myeloperoxidase activity (C), colon length (D), and TNF- α content (E). (F) Mice colonic tissues from various treatment groups. Reprinted from Wang C, Guo Z, Liang J, et al. An oral delivery vehicle based on konjac glucomannan acetate targeting the colon for inflammatory bowel disease therapy. *Front Bioeng Biotechnol.* 2022;10:1025155. Creative Commons.⁷⁵

Hybrid Targeting

Apart from the above mentioned passive or active targeting strategies that rely on single factors (pH, enzymes, ROS, receptors, etc.), researchers have attempted to design targeting strategies that rely on multiple factors to overcome the multiple biological challenges encountered with orally delivered nanoparticle systems.^{95,97–100} These targeting strategies, which combine different NP triggers, take advantage of the benefits of a single form while potentially mitigating its disadvantages to attain maximum effectiveness.

Mannose was abundant in cationic konjac glucomannan (cKGM) and selectively identified mannose receptors on the membranes of macrophages.^{151,152} The researchers used methacrylate-based gelatin (GelMA) loaded with cKGM and

ASO nanocomposite and embedded in pH-sensitive Eudragit FS30D to create pH and mannose receptor-responsive nanocomposites.⁹⁵ The alkaline environment of the colon promotes the release of nanocomplexes, and colonic macrophages can absorb ASO through mannose receptor-mediated endocytosis. According to the experimental data, colitis mice may benefit from the targeted release of nanonucleic acids into their colons, which may help reduce inflammation and mitigate damage. This could have an impact on how IBD is treated.

Additionally, infliximab was loaded into the oral NP delivery system by combining it with ROS-reactive cross-linkers and altering it with hyaluronic acid.⁹⁷ Two synthetic ROS-responsive cross-linkers, SS and TK linkers, are highly sensitive to ROS to protect the integrity of NPs and allow the release of antibodies in the inflamed intestinal mucosa. Hyaluronic acid-modified NPs target CD44 receptors and improve NP uptake by macrophages and colonic epithelial cells. In vivo experiments revealed that the NPs were more effective in terms of therapeutic efficacy than in the intravenous administration of infliximab (Figure 7).

Furthermore, carbon dots (CDs) have become essential nanomaterials due to their excellent stability and biocompatibility.¹⁵³ Researchers have prepared mannosylated nanocomposites by covalent polymerization of mannosylated NPs (Man-NPs) with CDs, and the glycosylation process is negatively charged due to the carboxyl group possessed on the main chain of inulin.⁹⁸ Man-NPs can bind selectively to the mannose receptor on the macrophage surface, leading to preferential cellular absorption.

Other Functional Effects

Other methods based on nano-delivery systems can be used to treat and diagnose IBD, in addition to using passive and active targeting strategies to target inflammatory colon tissue for drug action.

Immune regulation has a role in the pathogenesis of IBD. The spleen is the largest lymphoid organ and can regulate the immune system. A splenic-targeted PEG liposome (ST-H₂S lipo) loaded with H₂S donors was developed to treat UC by immunomodulation.³² According to a fluorescence assay against drug release, the fluorescence intensity of liposomes loaded with H₂S donors was higher than that of controls. ST-H₂S lipo exhibited significant absorption in the spleen following the intravenous drug administration. On the other hand, both conventional long-circulating liposomes (LC-H₂S lipo) and ST-H₂S lipo accumulated in the colon, with LC-H₂S lipo demonstrating a higher absorption rate. Compared to LC-H₂S liposomes, ST-H₂S liposomes had a more substantial immunomodulatory effect and a better therapeutic effect.

Restoring colon homeostasis using a microbiota-based strategy may be an effective IBD treatment. Nanomedicines containing components of cell membranes show promise as a therapeutic approach for managing a range of inflammatory diseases.⁴⁶ Scientists have recently developed a nanosystem with both antioxidant and anti-inflammatory functions (SeM@EM) by coating the surface of mesoporous silica NPs with a natural *E. coli* membrane that acted as a ROS scavenger. It was demonstrated that the NPs reduced inflammation and improved the adhesion of the drug. It is also remarkable how the NPs regulated the intestinal homeostatic balance and the growth of good intestinal microbiota.

Imaging IBD can be complex because the routinely used contrast agents (iodine-based and barium-based) are usually non-specific for the site of inflammation in IBD. Nahaet al developed a cerium oxide NP (Dex-CeNP) coated with dextrose anhydride as a contrast agent for IBD diagnostic imaging.¹⁵⁴ The presence of dextran provides good NP stability, biocompatibility, and specificity. Cerium oxide is also an antioxidant, neutralizing free radicals and reducing inflammation. Dex-CeNPs provide significant computed tomography contrast in the colon and accumulate in colitis-affected tissues. Notably, oral doses can nearly completely leave the body in 24 h.

Cerium dioxide NPs exhibit diverse enzymatic properties, such as superoxide dismutase and catalase activities, in addition to their capacity to scavenge hydroxyl radicals. Zhao et al combined cerium dioxide NPs and negatively charged montmorillonite to create the nanoenzyme complex.⁷⁰ When administered orally, the nanosystem targets the positively charged, inflamed colon and, in addition to its antioxidant properties, acts as montmorillonite to reduce bleeding.

Challenges and Future Perspectives

Despite substantial advancements in treating IBD based on nanodelivery techniques, there are still some issues and inefficiencies in the development process.




Figure 7 (A) IFXSS@HA/IFXTK@HA drug synthesis process and irritable bowel disease treatment mechanism. Colonic tissues (**B**), colonic length, and histopathologic histologic scores (**C**) of mice post-treatment in each group. Adapted from *Chem Eng J*, volume 445, Li X, Fang S, Yu Y, et al. Oral administration of inflammatory microenvironment-responsive carrier-free infliximab nanocomplex for the targeted treatment of inflammatory bowel disease. 136438, Copyright 2022, with permission from Elsevier.⁹⁷

Formulation improvement of drug preparation. Increased drug release from the colonic site and improved therapeutic efficacy can arise from formulation optimization of the product. For instance, multiple NPs were developed using various formulation ratios, and it was ultimately discovered that capryol 90 may be used as the carrier to enable complete drug release.⁴⁸

Improvement of the preparation process. Some preparation methods require a time-consuming, multi-step process with production scale restrictions, making the prepared NPs less stable. The drugs made partially by self-assembly have inadequate drug loading and low encapsulation rates. Problems regarding drug stability, loading discrepancies, and dimensional variations in the nano-delivery platform may also occur in large-scale production, whereas they do not occur in small batch production. Therefore, additional research on nano/micro-targeted drug delivery and developing new preparation processes is required to obtain a straightforward and dependable medication production.

Different results may stem from different experimental models. In vitro simulation experiments using NPs can produce positive findings regarding anti-inflammatory and antioxidant results. However, there are differences between experimental models (rodents) and human patient species. In vivo modeling of drug release and predicting stability of the gastrointestinal tract is challenging due to the complexity and individual heterogeneity of the gastrointestinal tract. For instance, the relevant targeting and therapeutic effect will be lessened if inflammation exists in other sites. Further research should be done to find an animal model that can accurately represent human IBD disease and imitate the pathophysiological environment of human IBD.

Optimal drug properties. Despite the excellent performance of the prepared NPs in trials, new designs must still be found to increase the precise release rate of the drug. The intended clinical outcome cannot be achieved by focusing on just one factor; instead, multiple combinations of strategies must be used. IBD treatment should include improving intestinal flora and re-establishing intestinal balance. Drug biocompatibility and biosafety should also be considered because nanocarriers may be toxic to the liver, kidneys, or other organs during their breakdown, metabolism, and excretion. Further experimental design and validation are required for some experimental results that did not investigate and understand the origins of the occurrence.

There are a number of potential issues to be addressed from the translation of nanomedicines to the clinic, including insufficient understanding of the mechanisms and chemical structure materials of NPs, safety profiles, regulatory and legal challenges. Therefore, the absorption and binding mechanisms during gastrointestinal transit still need to be studied in depth for the development of more advanced DDSs with more rational use of the pathological and physiological microenvironment. It is also essential to assess the long-term toxicity of DDSs and to develop relevant regulatory programmes. For drugs, more extensive multi-centre clinical studies are also needed to validate their efficacy. Concerted efforts by scientists and clinicians are needed in the development of nanomaterial drug delivery systems for the treatment of inflammatory diseases. The regulatory situation and ethical considerations pertaining to the development and application of nanoparticle-based therapeutics are also important factors to be taken into account in the context of translational research and clinical applications.

We are glad to note the innovative theories and strategies that nanotechnology has contributed to treating IBD and the diagnostic advancements it has brought about. The following qualities should be included in a perfect nanomedicine: A) it should be simple to make and can be mass-produced; B) it should be stable, with high drug loading and excellent drug release rates; C) it should have high target specificity, acting directly on the inflammatory colon site and releasing the drug continuously; and D) it should be easy to breakdown and absorb by the human body and should have good biosafety.

Conclusions

There is no complete treatment plan for IBD because it is a chronic idiopathic inflammatory disease with an unknown etiology. Every traditional therapeutic drug and treatment has disadvantages and causes more adverse effects and causes more adverse effects. Nano-agents, which can target and have various functional effects through both passive and active targeting, have been produced with the advancement of nanotechnology. Nanomedicines have demonstrated superior experimental therapeutic results. Currently, research on the clinical application of drug preparation, experimental design, and clinical application of drugs is still unsatisfactory. But these will be the areas of focus for future research. Future research will tend to the following aspects. Investigate the pathophysiological mechanism of the disease in more detail; develop novel drug delivery strategies by combining the research features of active and passive targeting; examine novel

experimental animal models to provide adequate pathological information for experiments; and screen optimal targeting drugs for early release into clinical practice.

Author Contributions

JG: Writing-reviewing and editing. JL: Conceptualization and methodology. ZL: Software. HW: Visualization and supervision. ZM: Funding acquisition. All authors made a significant contribution to the work reported, whether that is in the conception, study design, execution, acquisition of data, analysis and interpretation, or in all these areas; took part in drafting, revising or critically reviewing the article; gave final approval of the version to be published; have agreed on the journal to which the article has been submitted; and agree to be accountable for all aspects of the work.

Funding

This study was supported by Science and Technology Department of Jilin Province (Grant No. 20220505041ZP).

Disclosure

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

1. Maloy KJ, Powrie F. Intestinal homeostasis and its breakdown in inflammatory bowel disease. *Nature*. 2011;474(7351):298–306. doi:10.1038/nature10208
2. Alatab S, Sepanlou SG, Ikuta K. The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990–2017: a systematic analysis for the global burden of disease study 2017. *Lancet Gastroenterol Hepatol*. 2020;5(1):17–30. doi:10.1016/S2468-1253(19)30333-4
3. Ng SC, Shi HY, Hamidi N, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. *Lancet*. 2017;390(10114):2769–2778. doi:10.1016/S0140-6736(17)32448-0
4. Kaplan GG, Windsor JW. The four epidemiological stages in the global evolution of inflammatory bowel disease. *Nat Rev Gastroenterol Hepatol*. 2021;18(1):56–66. doi:10.1038/s41575-020-00360-x
5. Podolsky DK. Inflammatory bowel disease. *N Engl J Med*. 2002;347(6):417–429. doi:10.1056/NEJMr020831
6. Ott C, Schoelmerich J. Extraintestinal manifestations and complications in IBD. *Nat Rev Gastroenterol Hepatol*. 2013;10(10):585–595. doi:10.1038/nrgastro.2013.117
7. Ardizzone S, Puttini PS, Cassinotti A, et al. Extraintestinal manifestations of inflammatory bowel disease. *Digestive Liver Dis*. 2008;40:S253–S259. doi:10.1016/S1590-8658(08)60534-4
8. Ganji-Arjenaki M, Rafeian-Kopaei M, Malekzadeh M. Phytotherapies in inflammatory bowel disease. *J Res Med Sci*. 2019;24:24. doi:10.4103/jrms.JRMS_363_18
9. Ananthakrishnan AN, Bernstein CN, Iliopoulos D, et al. Environmental triggers in IBD: a review of progress and evidence. *Nat Rev Gastroenterol Hepatol*. 2018;15(1):39–49. doi:10.1038/nrgastro.2017.136
10. Bruner LP, White AM, Proksell S. Inflammatory bowel disease. *Prim Care*. 2023;50(3):411–427. doi:10.1016/j.pop.2023.03.009
11. Zhang S, Langer R, Traverso G. Nanoparticulate drug delivery systems targeting inflammation for treatment of inflammatory bowel disease. *Nano Today*. 2017;16:82–96. doi:10.1016/j.nantod.2017.08.006
12. Turner D, Ricciuto A, Lewis A, et al. STRIDE-II: an Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): determining Therapeutic Goals for Treat-to-Target strategies in IBD. *Gastroenterology*. 2021;160(5):1570–1583. doi:10.1053/j.gastro.2020.12.031
13. Lautenschläger C, Schmidt C, Fischer D, et al. Drug delivery strategies in the therapy of inflammatory bowel disease. *Adv Drug Delivery Rev*. 2014;71:58–76. doi:10.1016/j.addr.2013.10.001
14. Coco R, Plapied L, Pourcelle V, et al. Drug delivery to inflamed colon by nanoparticles: comparison of different strategies. *Int J Pharm*. 2013;440(1):3–12. doi:10.1016/j.ijpharm.2012.07.017
15. Ghosh S, Ghosh S, Sil PC. Role of nanostructures in improvising oral medicine. *Toxicol Rep*. 2019;6:358–368. doi:10.1016/j.toxrep.2019.04.004
16. Kietzmann D, Moulari B, Béduneau A, et al. Colonic delivery of carboxyfluorescein by pH-sensitive microspheres in experimental colitis. *Eur J Pharm Biopharm*. 2010;76(2):290–295. doi:10.1016/j.ejpb.2010.06.013
17. Kruis W, Kiudelis G, Racz I, et al. Once daily versus three times daily mesalazine granules in active ulcerative colitis: a double-blind, double-dummy, randomised, non-inferiority trial. *Gut*. 2009;58(2):233–240. doi:10.1136/gut.2008.154302
18. Date AA, Halpert G, Babu T, et al. Mucus-penetrating budesonide nanosuspension enema for local treatment of inflammatory bowel disease. *Biomaterials*. 2018;185:97–105. doi:10.1016/j.biomaterials.2018.09.005
19. Jeevanandam J, Barhoum A, Chan YS, et al. Review on nanoparticles and nanostructured materials: history, sources, toxicity and regulations. *Beilstein J Nanotechnol*. 2018;9:1050–1074. doi:10.3762/bjnano.9.98
20. Brakmane G, Winslet M, Seifalian AM. Systematic review: the applications of nanotechnology in gastroenterology. *Aliment. Pharmacol Ther*. 2012;36(3):213–221. doi:10.1111/j.1365-2036.2012.05179.x

21. Pontes AP, Welting TJM, Rip J, et al. Polymeric nanoparticles for drug delivery in osteoarthritis. *Pharmaceutics*. 2022;14(12):2639. doi:10.3390/pharmaceutics14122639
22. Marasini N, Er G, Fu C, et al. Development of a hyperbranched polymer-based methotrexate nanomedicine for rheumatoid arthritis. *Acta Biomater*. 2022;142:298–307. doi:10.1016/j.actbio.2022.01.054
23. Mai Y, Ouyang Y, Yu M, et al. Topical formulation based on disease-specific nanoparticles for single-dose cure of psoriasis. *J Control Release*. 2022;349:354–366. doi:10.1016/j.jconrel.2022.07.006
24. Brusini R, Varna M, Couvreur P. Advanced nanomedicines for the treatment of inflammatory diseases. *Adv Drug Delivery Rev*. 2020;157:161–178. doi:10.1016/j.addr.2020.07.010
25. Gazzaniga A, Maroni A, Sangalli ME, et al. Time-controlled oral delivery systems for colon targeting. *Expert Opin Drug Delivery*. 2006;3(5):583–597. doi:10.1517/17425247.3.5.583
26. Beloqui A, Coco R, Alhouayek M, et al. Budesonide-loaded nanostructured lipid carriers reduce inflammation in murine DSS-induced colitis. *Int J Pharm*. 2013;454(2):775–783. doi:10.1016/j.ijpharm.2013.05.017
27. Jakubiak P, Thwala LN, Cadete A, et al. Solvent-free protamine nanocapsules as carriers for mucosal delivery of therapeutics. *Eur Polym J*. 2017;93:695–705. doi:10.1016/j.eurpolymj.2017.03.049
28. El-Hady SM, AbouGhaly MH, El-Ashmoony MM, et al. Colon targeting of celecoxib nanomixed micelles using pulsatile drug delivery systems for the prevention of inflammatory bowel disease. *Int J Pharm*. 2020;576:118982.
29. Ali H, Weigmann B, Collnot E-M, et al. Budesonide loaded PLGA nanoparticles for targeting the inflamed intestinal mucosa-pharmaceutical characterization and fluorescence imaging. *Pharm Res*. 2016;33(5):1085–1092. doi:10.1007/s11095-015-1852-6
30. Vaezi Z, Aghdaei HA, Sedghi M, et al. Hemoglobin bio-adhesive nanoparticles as a colon-specific delivery system for sustained release of 5-aminosalicylic acid in the effective treatment of inflammatory bowel disease. *Int J Pharm*. 2022;616:121531.
31. Amaldoss MJN, Ahmed I, Kumar J, et al. Therapeutic efficacy of rifaximin loaded tamarind gum polysaccharide nanoparticles in TNBS induced IBD model Wistar rats. *Rep Pract Oncol Radiother*. 2021;26(5):712–729. doi:10.5603/RPOR.a2021.0100
32. Oh C, Lee W, Park J, et al. Development of spleen targeting H 2 s donor loaded liposome for the effective systemic immunomodulation and treatment of inflammatory bowel disease. *ACS nano*. 2023;17:4327–4345. doi:10.1021/acsnano.2c08898
33. Huguet-Casquero A, Xu Y, Gainza E, et al. Oral delivery of oleuropein-loaded lipid nanocarriers alleviates inflammation and oxidative stress in acute colitis. *Int J Pharm*. 2020;586:119515.
34. Kim JM, Kim DH, Park HJ, et al. Nanocomposites-based targeted oral drug delivery systems with infliximab in a murine colitis model. *J Nanobiotechnol*. 2020;18(1). doi:10.1186/s12951-020-00693-4
35. Li X, Hetjens L, Wolter N, et al. Charge-reversible and biodegradable chitosan-based microgels for lysozyme-triggered release of vancomycin. *J Adv Res*. 2023;43:87–96. doi:10.1016/j.jare.2022.02.014
36. Cheng S, Shen H, Zhao S, et al. Orally administered mesoporous silica capped with the cucurbit 8 uril complex to combat colitis and improve intestinal homeostasis by targeting the gut microbiota. *Nanoscale*. 2020;12(28):15348–15363. doi:10.1039/D0NR03037F
37. Moulari B, Pertuit D, Pellequer Y, et al. The targeting of surface modified silica nanoparticles to inflamed tissue in experimental colitis. *Biomaterials*. 2008;29(34):4554–4560. doi:10.1016/j.biomaterials.2008.08.009
38. Wang X, Yan -J, Wang L, et al. Rational design of polyphenol-poloxamer nanovesicles for targeting inflammatory bowel disease therapy. *Chem Mater*. 2018;30(12):4073–4080. doi:10.1021/acs.chemmater.8b01173
39. Penate Medina T, Pan J, Damoah C, et al. Utilizing sphingomyelinase sensitizing liposomes in imaging intestinal inflammation in dextran sulfate sodium-induced murine colitis. *Biomedicines*. 2022;10(2):413. doi:10.3390/biomedicines10020413
40. Priyam A, Shivhare K, Yadav S, et al. Enhanced solubility and self-assembly of amphiphilic sulfasalazine-PEG-OMe (S-PEG) conjugate into core-shell nanostructures useful for colonic drug delivery. *Colloids Surfaces, A*. 2018;547:157–167.
41. Ferri D, Gaviña P, Parra M, et al. Mesoporous silica microparticles gated with a bulky azo derivative for the controlled release of dyes/drugs in colon. *Royal Soc Open Sci*. 2018;5(8):180873. doi:10.1098/rsos.180873
42. Xu C, Chen S, Chen C, et al. Colon-targeted oral nanoparticles based on ROS-scavenging hydroxyethyl starch-curcumin conjugates for efficient inflammatory bowel disease therapy. *Int J Pharm*. 2022;623:121884.
43. Li S, Xie A, Li H, et al. A self-assembled, ROS-responsive Janus-prodrug for targeted therapy of inflammatory bowel disease. *J Control Release*. 2019;316:66–78. doi:10.1016/j.jconrel.2019.10.054
44. Zhang Q, Tao H, Lin Y, et al. A superoxide dismutase/catalase mimetic nanomedicine for targeted therapy of inflammatory bowel disease. *Biomaterials*. 2016;105:206–221. doi:10.1016/j.biomaterials.2016.08.010
45. Thu-Ha Thi N, Trinh N-T, Tran HN, et al. Improving silymarin oral bioavailability using silica-installed redox nanoparticle to suppress inflammatory bowel disease. *J Control Release*. 2021;331:515–524. doi:10.1016/j.jconrel.2020.10.042
46. Xu J, Shi T, Zhang Y, et al. Probiotic-inspired nanomedicine restores intestinal homeostasis in colitis by regulating redox balance, immune responses, and the gut microbiome. *Adv Mater*. 2022;35(3):2207890.
47. Zhang D, Wei Y, Chen K, et al. Biocompatible Reactive Oxygen Species (ROS)-responsive nanoparticles as superior drug delivery vehicles. *Adv Healthcare Mater*. 2015;4(1):69–76. doi:10.1002/adhm.201400299
48. Qelliny MR, Aly UF, Elgarhy OH, et al. Budesonide-loaded eudragit s 100 nanocapsules for the treatment of acetic acid-induced colitis in animal model. *AAPS Pharm Sci Tech*. 2019;20(6). doi:10.1208/s12249-019-1453-5
49. Zhang L, Li M, Zhang G, et al. Micro- and nanoencapsulated hybrid delivery system (MNEHDS): a novel approach for colon-targeted oral delivery of berberine. *Mol Pharmaceut*. 2021;18(4):1573–1581. doi:10.1021/acs.molpharmaceut.0c00970
50. Mutalik S, Suthar NA, Managuli RS, et al. Development and performance evaluation of novel nanoparticles of a grafted copolymer loaded with curcumin. *Int J Biol Macromol*. 2016;86:709–720. doi:10.1016/j.ijbiomac.2015.11.092
51. Cao J, Cheng J, Xi S, et al. Alginate/chitosan microcapsules for in-situ delivery of the protein, interleukin-1 receptor antagonist (IL-1Ra), for the treatment of dextran sulfate sodium (DSS)-induced colitis in a mouse model. *Eur J Pharm Biopharm*. 2019;137:112–121. doi:10.1016/j.ejpb.2019.02.011
52. Meissner Y, Pellequer Y, Lamprecht A. Nanoparticles in inflammatory bowel disease: particle targeting versus pH-sensitive delivery. *Int J Pharm*. 2006;316(1–2):138–143. doi:10.1016/j.ijpharm.2006.01.032

53. Jiang J, Xiao J, Zhao Z, et al. One-step prepared nano-in-micro microcapsule delivery vehicle with sequential burst-sustained drug release for the targeted treatment of inflammatory bowel disease. *Mater Chem Front*. 2021;5(16):6027–6040. doi:10.1039/D1QM00589H
54. Ali H, Weigmann B, Neurath MF, et al. Budesonide loaded nanoparticles with pH-sensitive coating for improved mucosal targeting in mouse models of inflammatory bowel diseases. *J Control Release*. 2014;183:167–177. doi:10.1016/j.jconrel.2014.03.039
55. Markam R, Bajpai J, Bajpai AK. Synthesis of ginger derived nanocarriers (GDNC) and study of in vitro release of 5-amino salicylic acid (5-ASA) as an anti inflammatory drug. *J Drug Delivery Sci Technol*. 2019;50:355–364. doi:10.1016/j.jddst.2019.01.039
56. Dong Y, Zhou Z, Ding H, et al. Preparation and properties of a pH sensitive carrier based on three kinds of polymer blend to control the release of 5-amino salicylic acid. *Pharmaceut Develop Technol*. 2014;19(8):960–967. doi:10.3109/10837450.2013.846372
57. Jacob EM, Borah A, Pillai SC, et al. Garcinol encapsulated pH-sensitive biodegradable nanoparticles: a novel therapeutic strategy for the treatment of inflammatory bowel disease. *Polymers*. 2021;13(6):862. doi:10.3390/polym13060862
58. Duan H, Lü S, Gao C, et al. Mucoadhesive microparticulates based on polysaccharide for target dual drug delivery of 5-aminosalicylic acid and curcumin to inflamed colon. *Colloids Surf B Biointerfaces*. 2016;145:510–519. doi:10.1016/j.colsurfb.2016.05.038
59. Qu Z, Wong KY, Moniruzzaman M, et al. One-pot synthesis of pH-responsive eudragit-mesoporous silica nanocomposites enable colonic delivery of glucocorticoids for the treatment of inflammatory bowel disease. *Adv Ther*. 2021;4(2). doi:10.1002/adtp.202000165
60. Kesharwani SS, Ahmad R, Bakkari MA, et al. Site-directed non-covalent polymer-drug complexes for inflammatory bowel disease (IBD): formulation development, characterization and pharmacological evaluation. *J Control Release*. 2018;290:165–179.
61. Kshirsagar SJ, Bhalekar MR, Patel JN, et al. Preparation and characterization of nanocapsules for colon-targeted drug delivery system. *Pharmaceut Develop Technol*. 2012;17(5):607–613. doi:10.3109/10837450.2011.557732
62. Nguyen CTH, Webb RI, Lambert LK, et al. Bifunctional succinylated epsilon-polylysine-coated mesoporous silica nanoparticles for pH-responsive and intracellular drug delivery targeting the colon. *ACS Appl Mater Interfaces*. 2017;9(11):9470–9483. doi:10.1021/acsami.7b00411
63. Naem M, Kim W, Cao J, et al. Enzyme/pH dual sensitive polymeric nanoparticles for targeted drug delivery to the inflamed colon. *Colloids Surf B Biointerfaces*. 2014;123:271–278. doi:10.1016/j.colsurfb.2014.09.026
64. Gonzalez-Alvarez M, Coll C, Gonzalez-Alvarez I, et al. Gated mesoporous silica nanocarriers for a “two-step” targeted system to colonic tissue. *Mol Pharmaceut*. 2017;14(12):4442–4453. doi:10.1021/acs.molpharmaceut.7b00565
65. Bertoni S, Liu Z, Correia A, et al. pH and reactive oxygen species-sequential responsive nano-in-micro composite for targeted therapy of inflammatory bowel disease. *Adv Funct Mater*. 2018;28(50):1806175.
66. Wang X, Yan J, Wang L, et al. Oral delivery of anti-TNF antibody shielded by natural polyphenol-mediated supramolecular assembly for inflammatory bowel disease therapy. *Theranostics*. 2020;10(23):10808–10822. doi:10.7150/thno.47601
67. Teruel AH, Pérez-Esteve É, González-álvarez I, et al. Smart gated magnetic silica mesoporous particles for targeted colon drug delivery: new approaches for inflammatory bowel diseases treatment. *J Control Release*. 2018;281:58–69. doi:10.1016/j.jconrel.2018.05.007
68. Wachsmann P, Moulari B, Béduneau A, et al. Surfactant-dependence of nanoparticle treatment in murine experimental colitis. *J Control Release*. 2013;172(1):62–68. doi:10.1016/j.jconrel.2013.07.031
69. Zhang S, Cho WJ, Jin AT, et al. Heparin-coated albumin nanoparticles for drug combination in targeting inflamed intestine. *Adv Healthcare Mater*. 2020;9(16):2000536.
70. Zhao S, Li Y, Liu Q, et al. An Orally Administered CeO₂@montmorillonite nanozyme targets inflammation for inflammatory bowel disease therapy. *Adv Funct Mater*. 2020;30(45). doi:10.1002/adfm.202004692
71. Shrestha N, Xu Y, Prévost JRC, et al. Impact of PEGylation on an antibody-loaded nanoparticle-based drug delivery system for the treatment of inflammatory bowel disease. *Acta Biomater*. 2022;140:561–572. doi:10.1016/j.actbio.2021.12.015
72. Li X, Yu M, Zhu Z, et al. Oral delivery of infliximab using nano-in-microparticles for the treatment of inflammatory bowel disease. *Carbohydr Polym*. 2021;273:118556. doi:10.1016/j.carbpol.2021.118556
73. Sunnap O, Subramanian S, Vemula PK, et al. Zingerone-encapsulated solid lipid nanoparticles as oral drug-delivery systems to potentially target inflammatory diseases. *Chemnanomat*. 2022;8(12). doi:10.1002/cnma.202200388
74. Zhang S, Ermann J, Succi MD, et al. An inflammation-targeting hydrogel for local drug delivery in inflammatory bowel disease. *Sci, trans med*. 2015;7(300). doi:10.1126/scitranslmed.aaa5657
75. Wang C, Guo Z, Liang J, et al. An oral delivery vehicle based on konjac glucomannan acetate targeting the colon for inflammatory bowel disease therapy. *Front Bioeng Biotechnol*. 2022;10:1025155.
76. Schilrreff P, Simioni YR, Jerez HE, et al. Superoxide dismutase in nanoarchaeosomes for targeted delivery to inflammatory macrophages. *Colloids Surf B Biointerfaces*. 2019;179:479–487. doi:10.1016/j.colsurfb.2019.03.061
77. Le Z, He Z, Liu H, et al. Antioxidant enzymes sequestered within lipid-polymer hybrid nanoparticles for the local treatment of inflammatory bowel disease. *ACS Appl Mater Interfaces*. 2021;13(47):55966–55977. doi:10.1021/acsami.1c19457
78. Vafaei SY, Esmaeili M, Amini M, et al. Self assembled hyaluronic acid nanoparticles as a potential carrier for targeting the inflamed intestinal mucosa. *Carbohydr Polym*. 2016;144:371–381. doi:10.1016/j.carbpol.2016.01.026
79. Gong W, Yu J, Zheng T, et al. CCL4-mediated targeting of spleen tyrosine kinase (Syk) inhibitor using nanoparticles alleviates inflammatory bowel disease. *Clin Translat Med*. 2021;11(2). doi:10.1002/ctm2.339
80. Zhang M, Viennois E, Prasad M, et al. Edible ginger-derived nanoparticles: a novel therapeutic approach for the prevention and treatment of inflammatory bowel disease and colitis-associated cancer. *Biomaterials*. 2016;101:321–340. doi:10.1016/j.biomaterials.2016.06.018
81. Shabana S, Hamouda HI, Abdalla M, et al. Multifunctional nanoparticles based on marine polysaccharides for apremilast delivery to inflammatory macrophages: preparation, targeting ability, and uptake mechanism*. *Int J Biol Macromol*. 2022;222:1709–1722. doi:10.1016/j.ijbiomac.2022.09.225
82. Huang Z, Gan J, Jia L, et al. An orally administrated nucleotide-delivery vehicle targeting colonic macrophages for the treatment of inflammatory bowel disease. *Biomaterials*. 2015;48:26–36. doi:10.1016/j.biomaterials.2015.01.013
83. Sinhmar GK, Shah NN, Rawal SU, et al. Surface engineered lipid nanoparticle-mediated site-specific drug delivery system for the treatment of inflammatory bowel disease. *Artif Cells Nanomed Biotechnol*. 2018;46:565–578. doi:10.1080/21691401.2018.1463232
84. Mao Y, Han M, Chen C, et al. A biomimetic nanocomposite made of a ginger-derived exosome and an inorganic framework for high-performance delivery of oral antibodies. *Nanoscale*. 2021;13(47):20157–20169. doi:10.1039/D1NR06015E

85. Herminia Higa L, Schilrreff P, Briski AM, et al. Bacterioruberin from Haloarchaea plus dexamethasone in ultra-small macrophage-targeted nanoparticles as potential intestinal repairing agent. *Colloids Surf B Biointerfaces*. 2020;191:110961.
86. Higa LH, Jerez HE, de Farias MA, et al. Ultra-small solid archaeolipid nanoparticles for active targeting to macrophages of the inflamed mucosa. *Nanomedicine*. 2017;12(10):1165–1175. doi:10.2217/nnm-2016-0437
87. Qiu H, Gong H, Bao Y, et al. Reactive oxygen species-scavenging hollow MnO₂ nanozymes as carriers to deliver budesonide for synergistic inflammatory bowel disease therapy. *Biomater Sci*. 2022;10(2):457–466. doi:10.1039/D1BM01525G
88. Bao M, Wang K, Li J, et al. ROS scavenging and inflammation-directed polydopamine nanoparticles regulate gut immunity and flora therapy in inflammatory bowel disease. *Acta Biomater*. 2023;161:250–264. doi:10.1016/j.actbio.2023.02.026
89. Naserifar M, Hosseinzadeh H, Abnous K, et al. Oral delivery of folate-targeted resveratrol-loaded nanoparticles for inflammatory bowel disease therapy in rats. *Life Sci*. 2020;262:118555. doi:10.1016/j.lfs.2020.118555
90. Huang Y, Guo J, Gui S. Orally targeted galactosylated chitosan poly(lactic-co-glycolic acid) nanoparticles loaded with TNF-alpha siRNA provide a novel strategy for the experimental treatment of ulcerative colitis. *Eur J Pharm Sci*. 2018;125:232–243. doi:10.1016/j.ejps.2018.10.009
91. Wei F, Lang Y, Shen Q, et al. Osteopontin-loaded PLGA nanoparticles enhance the intestinal mucosal barrier and alleviate inflammation via the NF-kappa B signaling pathway. *Colloids Surf B Biointerfaces*. 2020;190:110952.
92. Lee Y, Sugihara K, Gilliland MG, et al. Hyaluronic acid-bilirubin nanomedicine for targeted modulation of dysregulated intestinal barrier, microbiome and immune responses in colitis. *Nature Mater*. 2020;19(1):118. doi:10.1038/s41563-019-0462-9
93. Kotla NG, Burke O, Pandit A, et al. An orally administrated hyaluronan functionalized polymeric hybrid nanoparticle system for colon-specific drug delivery. *Nanomaterials*. 2019;9(9):1246. doi:10.3390/nano9091246
94. Du Y, Liu Y, Sun L, et al. cRGD peptide incorporated with patchouli alcohol loaded silk fibroin nanoparticles for enhanced targeting of inflammatory sites in colitis. *Biomater Advan*. 2022;140:101231.
95. Gan J, Liu Y, Sun L, et al. Orally administrated nucleotide-delivery particles from microfluidics for inflammatory bowel disease treatment. *Appl Mater Today*. 2021;25:101231.
96. Chen Y, Feng J, Chen Y, et al. ROS-responsive nano-medicine for navigating autophagy to enhance targeted therapy of inflammatory bowel disease. *Int J Pharm*. 2024;659:124117. doi:10.1016/j.ijpharm.2024.124117
97. Li X, Fang S, Yu Y, et al. Oral administration of inflammatory microenvironment-responsive carrier-free infliximab nanocomplex for the targeted treatment of inflammatory bowel disease. *Chem Eng J*. 2022;445:136438.
98. Sun Q, Arif M, Chi Z, et al. Macrophages-targeting mannosylated nanoparticles based on inulin for the treatment of inflammatory bowel disease (IBD). *Int J Biol Macromol*. 2021;169:206–215. doi:10.1016/j.ijbiomac.2020.12.094
99. Feng J, Wang Y, Lv Y, et al. XA pH-responsive and colitis-targeted nanoparticle loaded with shikonin for the oral treatment of inflammatory bowel disease in mice. *Mol Pharmaceut*. 2022;19(11):4157–4170. doi:10.1021/acs.molpharmaceut.2c00550
100. Lv Y, Ren M, Yao M, et al. Colon-specific delivery of methotrexate using hyaluronic acid modified pH-responsive nanocarrier for the therapy of colitis in mice. *Int J Pharm*. 2023;635:122741. doi:10.1016/j.ijpharm.2023.122741
101. Attia MF, Anton N, Wallyn J, et al. An overview of active and passive targeting strategies to improve the nanocarriers efficiency to tumour sites. *J Pharm Pharmacol*. 2019;71(8):1185–1198. doi:10.1111/jphp.13098
102. Lai SK, Wang -Y-Y, Hanes J. Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues. *Adv Drug Delivery Rev*. 2009;61(2):158–171. doi:10.1016/j.addr.2008.11.002
103. Lum H, Malik AB. Mechanisms of increased endothelial permeability. *Can J Physiol Pharmacol*. 1996;74(7):787–800. doi:10.1139/y96-081
104. Schulzke JD, Ploeger S, Amasheh M, et al. Epithelial tight junctions in intestinal inflammation. *Molec Struct Funct Tight Junct*. 2009;1165:294–300.
105. Lamprecht A, Yamamoto H, Takeuchi H, et al. Nanoparticles enhance therapeutic efficiency by selectively increased local drug dose in experimental colitis in rats. *J Pharmacol Exp Ther*. 2005;315(1):196–202. doi:10.1124/jpet.105.088146
106. Lamprecht A. IBD Selective nanoparticle adhesion can enhance colitis therapy. *Nat Rev Gastroenterol Hepatol*. 2010;7(6):311–312. doi:10.1038/nrgastro.2010.66
107. Lamprecht A, Schafer U, Lehr CM. Size-dependent bioadhesion of micro- and nanoparticulate carriers to the inflamed colonic mucosa. *Pharm Res*. 2001;18(6):788–793. doi:10.1023/A:1011032328064
108. Mukherjee S, Ray S, Thakur RS. Solid lipid nanoparticles: a modern formulation approach in drug delivery system. *Indian J Pharm Sci*. 2009;71(4):349–358. doi:10.4103/0250-474X.57282
109. Bondi ML, Montana G, Craparo EF, et al. Lipid nanoparticles as delivery vehicles for the Parietaria judaica major allergen Par j 2. *Int J Nanomed*. 2011;6:2953–2962. doi:10.2147/IJN.S24264
110. Harel-Adar T, Mordechai TB, Amsalem Y, et al. Modulation of cardiac macrophages by phosphatidylserine-presenting liposomes improves infarct repair. *Proc Natl Acad Sci U S A*. 2011;108(5):1827–1832. doi:10.1073/pnas.1015623108
111. Song W, Shen L, Wang Y, et al. Synergistic and low adverse effect cancer immunotherapy by immunogenic chemotherapy and locally expressed PD-L1 trap. *Nat Commun*. 2018;9. doi:10.1038/s41467-018-04605-x
112. Zwolinska-Wcislo M, Krzysiek-Maczka G, Ptak-Belowska A, et al. antibiotic treatment with ampicillin accelerates the healing of colonic damage impaired by aspirin and coxib in the experimental colitis. Importance of intestinal bacteria, colonic microcirculation and proinflammatory cytokines. *J Physiol Pharmacol*. 2011;62(3):357–368.
113. Ribeiro Paiotti AP, Miszputen SJ, Oshima CTF, et al. Effect of COX-2 inhibitor after TNBS-induced colitis in wistar rats. *J Molec Histol*. 2009;40(4):317–324. doi:10.1007/s10735-009-9243-0
114. Hong S, Choi DW, Kim HN, et al. Protein-based nanoparticles as drug delivery systems. *Pharmaceutics*. 2020;12(7):604. doi:10.3390/pharmaceutics12070604
115. Saptarshi SR, Duschl A, Lopata AL. Interaction of nanoparticles with proteins: relation to bio-reactivity of the nanoparticle. *J Nanobiotechnol*. 2013;11:11. doi:10.1186/1477-3155-11-11
116. Nayak AK, Pal D. Tamarind seed polysaccharide: an emerging excipient for pharmaceutical use. *Indian J Pharm Educ Res*. 2017;51(2):S136–S146. doi:10.5530/ijper.51.2s.60

117. Nakajima N, Ishihara K, Matsuura Y. Dietary-fiber-degrading enzymes from a human intestinal Clostridium and their application to oligosaccharide production from nonstarchy polysaccharides using immobilized cells. *Appl Microbiol Biotechnol*. 2002;59(2–3):182–189. doi:10.1007/s00253-002-1015-7
118. Ahn MY, Shin KH, Kim D-H, et al. Characterization of a Bacteroides species from human intestine that degrades glycosaminoglycans. *Can J Microbiol*. 1998;44(5):423–429. doi:10.1139/w98-027
119. Collins CE, Rampton DS. Review article: platelets in inflammatory bowel disease--pathogenetic role and therapeutic implications. *Aliment Pharmacol Ther*. 1997;11(2):237–247. doi:10.1046/j.1365-2036.1997.153328000.x
120. Ballongue J, Schumann C, Quignon P. Effects of lactulose and lactitol on colonic microflora and enzymatic activity. *Scand J Gastroenterol Suppl*. 1997;222:41–44. doi:10.1080/00365521.1997.11720716
121. Fahlgren A, Hammarström S, Danielsson Å, et al. Increased expression of antimicrobial peptides and lysozyme in colonic epithelial cells of patients with ulcerative colitis. *Clin Exp Immunol*. 2003;131(1):90–101. doi:10.1046/j.1365-2249.2003.02035.x
122. Rubio CA. The natural antimicrobial enzyme lysozyme is up-regulated in gastrointestinal inflammatory conditions. *Pathogens*. 2014;3(1):73–92. doi:10.3390/pathogens3010073
123. Roldo M, Barbu E, Brown JF, et al. Azo compounds in colon-specific drug delivery. *Expert Opin Drug Delivery*. 2007;4(5):547–560. doi:10.1517/17425247.4.5.547
124. Cao YH, Cao RH, Brakenhielm E. Antiangiogenic mechanisms of diet-derived polyphenols. *J Nutr Biochem*. 2002;13(7):380–390. doi:10.1016/S0955-2863(02)00204-8
125. Ayissi VBO, Ebrahimi A, Schluesenner H. Epigenetic effects of natural polyphenols: a focus on SIRT1-mediated mechanisms. *Mol Nutr Food Res*. 2014;58(1):22–32. doi:10.1002/mnfr.201300195
126. Ishida T, Wang X, Shimizu T, et al. PEGylated liposomes elicit an anti-PEG IgM response in a T cell-independent manner. *J Control Release*. 2007;122(3):349–355. doi:10.1016/j.jconrel.2007.05.015
127. Sakata A, Ochiai T, Shimeno H, et al. Acid sphingomyelinase inhibition suppresses lipopolysaccharide-mediated release of inflammatory cytokines from macrophages and protects against disease pathology in dextran sulphate sodium-induced colitis in mice. *Immunology*. 2007;122(1):54–64. doi:10.1111/j.1365-2567.2007.02612.x
128. Campbell EL, Colgan SP. Control and dysregulation of redox signalling in the gastrointestinal tract. *Nat Rev Gastroenterol Hepatol*. 2019;16(2):106–120. doi:10.1038/s41575-018-0079-5
129. Simmonds NJ, Rampton DS. Inflammatory bowel disease--a radical view. *Gut*. 1993;34(7):865–868. doi:10.1136/gut.34.7.865
130. Schulze-Osthoff K, Bauer MK, Vogt M, et al. Oxidative stress and signal transduction. *Internat J Vitam Nutr Res*. 1997;67(5):336–342.
131. Grisham MB. Oxidants and free radicals in inflammatory bowel disease. *Lancet*. 1994;344(8926):859–861. doi:10.1016/S0140-6736(94)92831-2
132. Pavlick KP, Laroux FS, Fuseler J, et al. Role of reactive metabolites of oxygen and nitrogen in inflammatory bowel disease. *Free Radic Biol Med*. 2002;33(3):311–322. doi:10.1016/S0891-5849(02)00853-5
133. Chen L, You Q, Hu L, et al. The antioxidant procyanidin reduces reactive oxygen species signaling in macrophages and ameliorates experimental colitis in mice. *Front Immunol*. 2017;8:1910. doi:10.3389/fimmu.2017.01910
134. Simmonds NJ, Allen RE, Stevens TRJ, et al. Chemiluminescence assay of mucosal reactive oxygen metabolites in inflammatory bowel disease. *Gastroenterology*. 1992;103(1):186–196. doi:10.1016/0016-5085(92)91112-H
135. Sedghi S, Fields JZ, Klamut M, et al. Increased production of luminol enhanced chemiluminescence by the inflamed colonic mucosa in patients with ulcerative colitis. *Gut*. 1993;34(9):1191–1197. doi:10.1136/gut.34.9.1191
136. Nugent SG, Kumar D, Rampton DS, et al. Intestinal luminal pH in inflammatory bowel disease: possible determinants and implications for therapy with aminosaliculates and other drugs. *Gut*. 2001;48(4):571–577. doi:10.1136/gut.48.4.571
137. Palugan L, Cerea M, Zema L, et al. Coated pellets for oral colon delivery. *J Drug Delivery Sci Technol*. 2015;25:1–15. doi:10.1016/j.jddst.2014.12.003
138. Naik JB, Waghulde MR. Development of vildagliptin loaded Eudragit microspheres by screening design: in vitro evaluation. *J Pharm Invest*. 2018;48(6):627–637. doi:10.1007/s40005-017-0355-3
139. Madhavi M, Madhavi K, Jithan AV. Preparation and in vitro/in vivo characterization of curcumin microspheres intended to treat colon cancer. *J Pharm Bioallied Sci*. 2012;4(2):164–171. doi:10.4103/0975-7406.94825
140. Asfour MH, Mohsen AM. Formulation and evaluation of pH-sensitive rutin nanospheres against colon carcinoma using HCT-116 cell line. *J Adv Res*. 2018;9:17–26. doi:10.1016/j.jare.2017.10.003
141. Kulkarni RV, Sa B. Evaluation of pH-Sensitivity and Drug Release Characteristics of (Polyacrylamide-Grafted-Xanthan)-Carboxymethyl Cellulose-Based pH-Sensitive interpenetrating network hydrogel beads. *Drug Dev Ind Pharm*. 2008;34(12):1406–1414. doi:10.1080/03639040802130079
142. Das S, Chaudhury A, Ng K-Y. Preparation and evaluation of zinc-pectin-chitosan composite particles for drug delivery to the colon: role of chitosan in modifying in vitro and in vivo drug release. *Int J Pharm*. 2011;406(1–2):11–20. doi:10.1016/j.ijpharm.2010.12.015
143. Ways TMM, Lau WM, Khutoryanskiy VV. Chitosan and Its Derivatives for Application in Mucoadhesive Drug Delivery Systems. *Polymers*. 2018;10(3):267. doi:10.3390/polym10030267
144. Maroni A, Moutaharrik S, Zema L, et al. Enteric coatings for colonic drug delivery: state of the art. *Expert Opin Drug Delivery*. 2017;14(9):1027–1029. doi:10.1080/17425247.2017.1360864
145. Tirosh B, Khatib N, Barenholz Y, et al. Transferrin as a luminal target for negatively charged liposomes in the inflamed colonic mucosa. *Mol Pharmaceut*. 2009;6(4):1083–1091. doi:10.1021/mp9000926
146. Wileman TE, Lennartz MR, Stahl PD. Identification of the macrophage mannose receptor as a 175-kDa membrane protein. *Proc Natl Acad Sci USA*. 1986;83(8):2501–2505. doi:10.1073/pnas.83.8.2501
147. Leonel Parra F, Stoll IK, Zwick M, et al. Make It Simple: (SR-A1+TLR7) Macrophage Targeted NANOarchaeosomes. *Front Bioeng Biotechnol*. 2018;6:6. doi:10.3389/fbioe.2018.00006
148. Tripodo G, Trapani A, Torre ML, et al. Hyaluronic acid and its derivatives in drug delivery and imaging: recent advances and challenges. *Eur J Pharm Biopharm*. 2015;97:400–416. doi:10.1016/j.ejpb.2015.03.032
149. de la Motte CA, Kessler SP. The role of hyaluronan in innate defense responses of the intestine. *Int J Cell Biol*. 2015;2015:481301. doi:10.1155/2015/481301

150. Mukaida N, Sasaki S-I, Baba T. CCL4 Signaling in the Tumor Microenvironment. In: Birbrair A, editor. *Tumor Microenvironment: The Role of Chemokines, Pt A*. Springer; 2020:23–32.
151. Schreiber S, Perkins SL, Teitelbaum SL, et al. Regulation of mouse bone marrow macrophage mannose receptor expression and activation by prostaglandin E and IFN-gamma. *J Immunol*. 1993;151(9):4973–4981. doi:10.4049/jimmunol.151.9.4973
152. Lane KB, Egan B, Vick S, et al. Characterization of a rat alveolar macrophage cell line that expresses a functional mannose receptor. *J Leukoc Biol*. 1998;64(3):345–350. doi:10.1002/jlb.64.3.345
153. Janus L, Piatkowski M, Radwan-Pragłowska J. Microwave-assisted synthesis and characterization of Poly(L-lysine)-Based Polymer/carbon quantum dot nanomaterials for biomedical purposes. *Materials*. 2019;12(23):3825. doi:10.3390/ma12233825
154. Naha PC, Hsu JC, Kim J, et al. Dextran-coated cerium oxide nanoparticles: a computed tomography contrast agent for imaging the gastrointestinal tract and inflammatory bowel disease. *Acs Nano*. 2020;14(8):10187–10197. doi:10.1021/acsnano.0c03457

Drug Design, Development and Therapy

Dovepress

Publish your work in this journal

Drug Design, Development and Therapy is an international, peer-reviewed open-access journal that spans the spectrum of drug design and development through to clinical applications. Clinical outcomes, patient safety, and programs for the development and effective, safe, and sustained use of medicines are a feature of the journal, which has also been accepted for indexing on PubMed Central. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/drug-design-development-and-therapy-journal>